Document:

<Page>

WHENEVER CONFIDENTIAL INFORMATION IS OMITTED HEREIN (SUCH OMISSIONS ARE DENOTED
BY AN ASTERISK*), SUCH CONFIDENTIAL INFORMATION HAS BEEN SUBMITTED SEPARATELY TO
THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT.

                                LICENSE AGREEMENT

     This Agreement is made and entered into this 9th day of September, 2003
(the "Effective Date") by and between Metabolix, Inc., a corporation duly
organized and existing under the laws of the State of Delaware and having its
principal office at 303 Third Street, Cambridge, Massachusetts 02142
(hereinafter referred to as "Metabolix"), and Tepha, Inc., a corporation duly
organized and existing under the laws of the State of Delaware and having its
principal office at 303 Third Street, Cambridge, Massachusetts 02142
(hereinafter referred to as "Tepha").

     WHEREAS, Metabolix is the assignee from Monsanto Company ("Monsanto") of
all right, title and interest in the Patent Rights, Biological Materials and
Know-How (all as defined herein);

     WHEREAS, Metabolix wishes to grant, and Tepha wishes to receive, license
rights to the Patent Rights, Biological Materials and Know-How; and

     WHEREAS, the grant of such license rights is subject to the prior written
approval of Monsanto, which has been obtained, and a copy of which is attached
as Appendix D for reference only.

     NOW THEREFORE, in consideration of the premises and the mutual covenants
contained herein, the parties hereto agree as follows:

1.   DEFINITIONS.

     1.1.  "Patent Rights" shall mean: (i) the U.S. and foreign patent
           applications and patents set forth in Appendix A, and the inventions
           described and/or claimed therein, and all other patent rights
           assigned to Metabolix by Monsanto not relating to plant crop
           production of PHAs shall be added to Appendix A by amendment; (ii)
           any divisionals, continuations and continuation-in-part applications
           which shall be directed to subject matter specifically described in
           such patent applications; (iii) the resulting U.S. and foreign
           patents; (iv) any reissues, reexaminations or extensions of such
           patents; and (v) all foreign counterparts of the above patent
           applications and patents. For the avoidance of doubt, the Patent
           Rights do not include any of the Zeneca Limited patent rights
           licensed to Metabolix by Monsanto in the Patent Sub-License Agreement
           dated May 14, 2001.

     1.2.  "Biological Materials" shall mean the biological materials set forth
           in Appendix B, and all Progeny and Unmodified Derivatives of those
           materials, but excluding Modifications. "Progeny" shall mean an
           unmodified descendant from the Biological Materials, such as virus
           from virus, cell from cell, or organism from organism. "Unmodified
           Derivatives" shall mean substances created by Tepha which constitute
           an unmodified functional subunit or product expressed by the
           Biological Material(s), (some examples include: subclones of
           unmodified cell

*    CONFIDENTIAL TREATMENT REQUESTED

<Page>

           lines, purified or fractionated subsets of the Biological
           Material(s), proteins expressed by DNA/RNA supplied by Metabolix, or
           monoclonal antibodies secreted by a hybridoma cell line).

     1.3.  "Modifications" shall mean substances created by Tepha that
           contain/incorporate Biological Material(s).

     1.4.  "Know-How" shall mean the know-how set forth in Appendix C.

     1.5.  "Field" shall mean IN VIVO human and veterinary medical use of
           polymers falling within the Patent Rights, including, without
           limitation, tissue engineering, cell therapy, implantables, medical
           devices, wound sealants, prescription and non-prescription drug
           delivery, and contrast agents, but excluding (i) medical disposables,
           surgical drapes and trays, sanitary products, barrier contraceptives,
           nutritional and all other diagnostic uses and (ii) transgenic plant
           crop production of polymers. For the purpose of clarity, it is agreed
           and understood that, notwithstanding anything in the prior sentence
           to the contrary, diagnostic systems and/or devices used to monitor
           the IN VIVO use of a Licensed Product shall be included within the
           Field. For the purpose of determining whether a use falls within the
           Field, the parties shall apply the following guidelines: (x)
           regulation of a use by the U.S. Food and Drug Administration or other
           regulatory body shall be indicative but not presumptive that a use is
           an IN VIVO use, and (y) uses marketed only to physicians shall
           primarily fall within the Field, and (z) uses marketed directly only
           to consumers shall primarily fall outside the Field.

     1.6.  "Net Sales shall mean Tepha's billings for the use, sale, lease or
           other disposition of Licensed Products and Licensed Processes, and
           the fair market value of noncash consideration, less:

           1.6.1  discounts allowed in amounts customary in the trade;

           1.6.2  sales, tariff duties and/or use taxes directly imposed and
                  with reference to particular sales;

           1.6.3  outbound transportation prepaid or allowed; and

           1.6.4  amounts allowed or credited on returns.

     No deduction shall be made for commissions paid to individuals whether they
     be with independent sales agencies or regularly employed by Licensee and on
     its payroll, or for cost of collections. Licensed Products shall be
     considered "sold" when invoiced. "Net Sales" shall not include Licensed
     Products sold for clinical testing, research or development. If a Licensed
     Product or Licensed Process shall otherwise be distributed or invoiced for
     a discounted price substantially lower than customary in the trade or
     distributed at no cost to Tepha Affiliates or otherwise, Net Sales shall be
     based on the customary amount billed for such Licensed Products or Licensed
     Processes.

     Where the Licensed Product is a combination product consisting of material
     whose composition or manufacture is covered by the Patent Rights ("Patented
     Material") plus other materials (such as a growth factor, but not, for
     example, filler materials) that are not

*    CONFIDENTIAL TREATMENT REQUESTED

                                        2

<Page>

     covered by the Patent Rights, then "Net Sales" shall mean the Net Sales of
     the full product multiplied by the fully loaded manufacturing cost of the
     Patented Material divided by the total fully loaded manufacturing cost of
     the total combination product. When the Licensed Product consists of a
     combination product consisting of a component made from the Patented
     Material plus other components, then "Net Sales" shall mean Net Sales of
     the total product multiplied by the fully loaded manufacturing cost of the
     Patented Material component divided by the fully loaded manufacturing cost
     of the total product. By "fully loaded" is meant the cost of goods sold
     plus overhead allocated to production and sale thereof.

     1.7.  "Tepha" and "Metabolix" shall include "Affiliates." "Affiliates"
           shall mean a related company of Tepha or Metabolix, respectively, the
           voting stock of which is directly or indirectly at least fifty
           percent (50%) owned and controlled by Tepha or Metabolix, an
           organization which directly or indirectly controls more than fifty
           percent (50%) of the voting stock of Tepha or Metabolix, and an
           organization the majority ownership of which is directly or
           indirectly common to the ownership of Tepha or Metabolix.

     1.8.  "Licensed Process" means any process which is covered in whole or in
           part by an issued, unexpired valid claim or a pending claim contained
           in the Patent Rights in the country in which such process is used or
           in which the Licensed Product made thereby is used or sold.

     1.9.  "Licensed Product" means any product or part thereof which: (i) is
           covered in whole or in part by an issued, unexpired valid claim or a
           pending claim contained in the Patent Rights in the country in which
           any such product or part thereof is made, used or sold; or (ii) is
           manufactured by using a process or is employed to practice a process
           which is covered in whole or in part by an issued unexpired valid
           claim or a pending claim contained in the Patent Rights in the
           country in which a Licensed Process is used or in which such product
           or part thereof is used or sold.

2.   LICENSE GRANT AND OWNERSHIP

     2.1.  NONEXCLUSIVE LICENSE. Subject to the terms and conditions of this
           Agreement, Metabolix hereby grants to Tepha the worldwide,
           nonexclusive right and license, with the right to sublicense, in the
           Field: (i) under the Patent Rights to make, have made, use, lease,
           sell, offer for sale and import the Licensed Products and to practice
           the Licensed Processes until the expiration of the last to expire of
           the Patent Rights, unless this Agreement shall be sooner terminated
           according to the terms hereof; (ii) to make, have made, use, lease,
           sell, offer for sale, import and create Modifications of the
           Biological Materials; and (iii) to use Know-How.

     2.2.  EXCLUSIVE LICENSE. Subject to the terms and conditions of this
           Agreement, Metabolix hereby grants to Tepha the worldwide,
           royalty-free, exclusive right and license, with the right to
           sublicense, in the Field to make, have made, use, lease, sell, offer
           for sale and import Modifications.

*    CONFIDENTIAL TREATMENT REQUESTED

                                        3

<Page>

     2.3.  DELIVERY. Tepha shall have thirty (30) days after the Effective Date
           to review and make copies of the Know-How and Biological Materials.
           Metabolix makes no representations regarding the viability of any of
           the Biological Materials. After thirty (30) days from the Effective
           Date, any request to review or make copies of the Know-How or
           Biological Materials shall be at Metabolix's discretion.

     2.4.  OWNERSHIP OF MODIFICATIONS. Tepha hereby assigns to Metabolix all of
           its right, title and interest in and to the Modifications, including
           any and all intellectual property rights therein. Tepha also agrees
           to promptly execute all assignments and patent applications, and
           similar documents as reasonably requested by Metabolix. If Metabolix
           shall be unable to obtain Tepha's execution of such documents for any
           reason, Tepha hereby irrevocably appoints Metabolix and its agents as
           Tepha's agents and attorneys-in-fact to execute such documents with
           the same legal effect as if Tepha shall have executed them.

     2.5.  RIGHT TO SUBLICENSE. Tepha's right to sublicense in Paragraphs 2.1
           and 2.2 is subject to Metabolix' prior written approval during the
           period that Metabolix requires Monsanto's approval to sublicense.
           Tepha agrees to insert a provision in each sublicense that Metabolix
           is a third party beneficiary of the sublicense as to the sublicensed
           Patent Rights, with the right to enforce the applicable terms thereof
           in the event Tepha does not enforce its rights.

     2.6.  NO OTHER RIGHTS. Nothing in this Agreement shall be construed to
           confer any rights upon Tepha by implication, estoppel or otherwise
           beyond the express licenses granted by Metabolix or as to any
           technology or patent rights of Metabolix or any other entity other
           than the Patent Rights, Biological Materials and Know-How.

     2.7.  MONSANTO RIGHTS. Monsanto retains certain rights to Patent Rights as
           collateral in the event of default by Metabolix under a Security
           Agreement between Monsanto and Metabolix dated May 12, 2001, and this
           Agreement is subject to Monsanto's rights therein. Monsanto has
           granted its approval of this Agreement in the letter attached as
           Appendix D; however, Monsanto retains all of its rights during the
           remaining term of the Security Agreement, including without
           limitation its rights to Patent Rights as collateral, and in the
           event Tepha exercises its right to sublicense third parties, such
           sublicenses shall also be subject to such Monsanto's rights.

3.   ROYALTIES

     3.1.  LICENSE ISSUE FEE. In partial consideration for the license rights
           granted herein, Tepha shall pay Metabolix a License Issue Fee of *
           which shall be deemed earned and due as follows: * on the Effective
           Date, and * on each of the six-month, twelve-month and
           eighteenth-month anniversaries of the Effective Date; provided,
           however, the balance of the full amount of such License Issue Fee
           shall be due upon the raising by Tepha of * (cumulatively) after the
           Effective Date in investment capital and/or research and development
           funds in connection with the

*    CONFIDENTIAL TREATMENT REQUESTED

                                        4

<Page>

           Patent Rights, Biological Materials and Know-How, and payment shall
           be made within thirty (30) days thereafter.

     3.2   RUNNING ROYALTIES. In partial consideration for the license rights
           granted herein, Tepha shall pay Metabolix running royalties of * of
           Net Sales by Tepha ("Running Royalty"); provided, however, the
           maximum cumulative Running Royalties due on particular Net Sales of
           any Licensed Product or Licensed Process payable by Tepha to
           Metabolix for any quarter under (i) this Agreement, and (ii) the
           sublicense from Metabolix to Tepha to certain Massachusetts Institute
           of Technology patent rights dated October 1, 1999, as amended, shall
           be * of such Net Sales, subject to any deductions permitted under
           Paragraph 3.7.

     3.3   SUBLICENSE REVENUE. Tepha shall pay Metabolix a * share of gross
           sublicensing revenue, including sublicense issue fees, milestone
           payments, license maintenance fees, royalties on net sales, and
           similar consideration, and including, for the avoidance of doubt, the
           fair market value of any sublicense rights granted in a multi-part
           transaction, but excluding research and development funding received
           by Tepha; provided, however, the maximum cumulative share of gross
           sublicensing revenue in regard to a particular sublicense payable by
           Tepha to Metabolix for any quarter under (i) this Agreement, and (ii)
           the sublicense from Metabolix to Tepha to certain Massachusetts
           Institute of Technology patent rights dated October 1, 1999, as
           amended, shall be * of such gross sublicensing revenue. For purposes
           herein, sublicensees' net sales shall have a parallel meaning to the
           definition of Tepha's Net Sales in Paragraph 1.6.

     3.4   PAYMENTS IN FULL. All payments due hereunder shall be paid in full,
           without deduction of taxes or other fees which may be imposed by any
           government, except as otherwise provided in Paragraph 1.6.2.

     3.5   NO MULTIPLE ROYALTIES. No multiple Running Royalties shall be payable
           because any Licensed Product or Licensed Process, its manufacture,
           use, sale or importation are or shall be covered by more than one
           patent application or patent licensed under this Agreement.

     3.6   PAYMENT. Royalty payments shall be paid in the United States dollars
           in Cambridge, Massachusetts, or at such other place as Metabolix may
           reasonably designate consistent with the laws and regulations
           controlling in any foreign country. If any currency conversion shall
           be required in connection with the payment of royalties hereunder,
           such conversion shall be made by using the exchange rate published in
           the Wall Street Journal on the last business day of the calendar
           quarterly reporting period to which such royalty payments relate.

     3.7   THIRD PARTY LICENSES. To the extent that Tepha has executed or shall
           obtain subsequent to the Effective Date licenses to third party
           patents or other intellectual property that are necessary to
           manufacture or sell Licensed Products or Licensed Processes in the
           Field, Tepha may deduct from the Running Royalty due to Metabolix
           under Paragraph 3.2, * of the running royalties due on such third

*    CONFIDENTIAL TREATMENT REQUESTED

                                        5

<Page>

           party patents or intellectual property up to an amount equal to * of
           the Running Royalties due hereunder.

     3.8   APPLICATION OF CREDITS. Any credits against Running Royalties
           permitted under this Agreement may be applied by Tepha, cumulatively,
           up to * the Running Royalties otherwise due in the respective
           quarterly accounting period; provided, Tepha may carry over unused
           credits to subsequent quarterly accounting periods. Notwithstanding
           the applicability of credits under one or more Paragraphs of this
           Agreement, the minimum Running Royalties due from Tepha shall be * of
           the Running Royalties otherwise payable, subject to the maximum set
           forth in Paragraph 3.2.

4.   PATENT PROSECUTION

     4.1.  PATENT PROSECUTION. Throughout the term of this Agreement, Metabolix,
           at its own expense, shall file, prosecute and maintain the Patent
           Rights. If Metabolix shall elect not to file, prosecute or maintain
           any Patent Right, Metabolix shall notify Tepha in writing with at
           least thirty (30) days notice prior to any filing, action, payment or
           the like being due, in which event Tepha shall have the right to
           file, prosecute or maintain such Patent Right, at Tepha's expense in
           Metabolix' name. Metabolix agrees to execute, and agrees to use
           reasonable efforts to ensure that its employees shall execute, all
           documents necessary to perfect filing, advance prosecution and/or
           effect issue of any patents upon any such applications. After notice
           of such election by Metabolix, Tepha shall have no further royalty
           obligations under Paragraphs 3.2 and 3.3 with respect to such patents
           or applications.

5.   RECORDS AND PAYMENTS

     5.1.  RECORDS AND AUDIT. Tepha shall keep true and accurate books of
           account containing all particulars that may be necessary for the
           purpose of showing the amounts payable to Metabolix hereunder. Said
           books of account shall be kept at Tepha's principal place of business
           and shall be open at all reasonable times for three (3) years
           following the end of the calendar year to which they pertain, to the
           inspection of Metabolix or its agents for the purpose of verifying
           Tepha's royalty statements or compliance in other respect with this
           Agreement. Should such inspection lead to the discovery of a greater
           than Ten Percent (10%) discrepancy in reporting to Metabolix's
           detriment, Tepha agrees to pay the cost of such inspection.

     5.2.  REPORTS AND PAYMENTS. Within thirty (30) days after the end of each
           calendar quarter during the term of this Agreement, Tepha shall send
           to Metabolix a report showing the Net Sales of the Licensed Products
           and Licensed Processes, including calculation of deductions, and
           sublicensing gross revenue for such quarter and shall pay the
           appropriate royalties to Metabolix.

*    CONFIDENTIAL TREATMENT REQUESTED

                                        6

<Page>

     5.3.  INTEREST. The amounts due under Articles 3 shall, if overdue, bear
           interest until payment at a per annum rate * above * in effect at
           Fleet Bank, or its successors, on the due date. The payment of such
           interest shall not foreclose Metabolix from exercising any other
           rights it may have as a consequence of the lateness of any payment.

6.   DUE DILIGENCE

     6.1.  DILIGENT EFFORTS. Tepha shall use diligent efforts to bring one or
           more Licensed Products or Licensed Processes to market through a
           thorough, vigorous and diligent program for exploitation of the
           Patent Rights and shall continue active, diligent development and
           marketing efforts for one or more Licensed Products or Licensed
           Processes throughout the term of this Agreement

     6.2.  GOVERNMENTAL APPROVALS AND MARKETING OF LICENSED PRODUCTS. Tepha or
           its designees shall be responsible for obtaining all necessary
           governmental approvals for the development, production, distribution,
           sale and use of any Licensed Product, at Tepha's, or its designees',
           expense, including, without limitation, any safety studies. Tepha or
           its designees shall have sole responsibility for any warning labels,
           packaging and instructions as to the use of Licensed Products and for
           the quality control for any Licensed Product.

7.   INFRINGEMENT

     7.1.  NOTICE. Tepha and Metabolix shall each inform the other promptly in
           writing of any alleged or threatened infringement of the Patent
           Rights by a third party and of any available evidence thereof.

     7.2.  PURSUIT OF INFRINGERS. During the term of this Agreement, Tepha shall
           have the right, but shall not be obligated, to prosecute at its own
           expense all infringements of the Patent Rights by a third party in
           the Field by litigation or settlement discussions and, in furtherance
           of such right, Metabolix agrees that Tepha may join Metabolix as a
           party plaintiff in any such suit, without expense to Metabolix. The
           total cost of any such infringement action commenced solely by Tepha
           shall be borne by Tepha. In the event that Tepha shall have exercised
           its right to bring an action, Tepha shall be responsible for
           defending against any counterclaims alleging invalidity or
           unenforceability of a Patent Right and for prosecuting the action
           through to settlement or other final disposition. In the event that
           Tepha shall undertake the enforcement of the Patent Rights in the
           Field by litigation, Tepha may withhold up to * of the Running
           Royalties otherwise thereafter due to Metabolix under Paragraph 3.2
           and apply the same toward reimbursement of up to * of Tepha's
           expenses, including reasonable attorneys' fees, in connection
           therewith.

     7.3.  If within six (6) months after having been notified of any alleged
           infringement, Tepha shall have been unsuccessful in persuading the
           alleged infringer to desist and shall not have brought and shall not
           be diligently prosecuting an infringement

*    CONFIDENTIAL TREATMENT REQUESTED

                                        7

<Page>

           action, or if Tepha shall notify Metabolix at any time prior thereto
           of its intention not to bring suit against any alleged infringer,
           then, and in those events, only, Metabolix shall have the right, but
           shall not be obligated, to prosecute at its own expense any
           infringement of the Patent Rights in the Field. In furtherance of
           such right, Tepha hereby agrees that Metabolix may include Tepha as a
           party plaintiff in any such suit, without expense to Tepha. The total
           cost of any such infringement action commenced or defended solely by
           Metabolix shall be borne by Metabolix, and Metabolix shall be
           responsible for defending against any counterclaims alleging
           invalidity or unenforceability of a Patent Right.

     7.4.  Any recovery of damages by the prosecuting party for any such suit
           shall be applied first in satisfaction of any unreimbursed expenses
           and legal fees of such party relating to the suit, and next toward
           reimbursement of Metabolix for any royalties past due or withheld and
           applied pursuant to Paragraph 7.2, if applicable. The balance
           remaining from any such recovery shall be divided with * to the
           non-prosecuting party and any remaining balance to the prosecuting
           party.

     7.5.  In the event of the institution of any suit by a third party against
           Metabolix, Tepha or its sublicensees for patent infringement
           involving the Patent Rights in the Field, the party sued shall
           promptly notify the other party in writing. Tepha shall have the
           right, but not the obligation, to defend such suit at its own
           expense. If Tepha shall elect not to defend, Tepha shall promptly
           notify Metabolix. Metabolix shall have the right, but not the
           obligation, to defend such suit at its expense.

     7.6.  If Tepha shall exercise its rights pursuant to Section 7.5 to defend
           the Patent Rights, then * of Tepha's Running Royalty obligation in
           Paragraph 3.2 during the pendency of defense in the proceeding shall
           be held in an interest-bearing escrow account by Tepha until a final
           decision shall be rendered by a court or administrative tribunal of
           competent jurisdiction from which no appeal can be or is taken
           provided that:

           7.6.1  If the enforceability of all material claims in such Patent
                  Right claiming the Licensed Product or Licensed Process is
                  upheld by a court of other legal or administrative tribunal
                  from which no appeal is or can be taken, then the amount of
                  Running Royalties withheld during the period of escrow, plus
                  all accrued interest, shall be promptly paid to Metabolix; or

           7.6.2  If one or more claims in such Patent Right covering the
                  Licensed Product or Licensed Process shall be held to be
                  invalid or otherwise unenforceable by a court or other legal
                  or administrative tribunal in any country from which no appeal
                  is or can be taken or the scope thereof is modified and, as a
                  result such Patent Right no longer offers substantial
                  protection to a Licensed Product or Licensed Process in such
                  country, then the amount of Running Royalties withheld during
                  the period of escrow shall not be owed to Metabolix; Tepha
                  shall be entitled to all payments and accrued interest in the
                  escrow account; and the Running Royalties otherwise payable
                  shall

*    CONFIDENTIAL TREATMENT REQUESTED

                                        8

<Page>

                  be abated in their entirety with respect to Net Sales of
                  Licensed Products or Licensed Processes covered only by such
                  Patent Right in the country in which such claims were so held
                  invalid or unenforceable or so modified.

     7.7.  In any suit as either party may institute to enforce or defend the
           Patent Rights pursuant to this Agreement, the other party hereto
           shall, at the request and expense of the party initiating such suit,
           cooperate in all respects and, to the extent possible, have its
           employees testify when requested and make available relevant records,
           papers, information, samples, specimens and the like. The parties
           shall keep one another informed of the status of and of their
           respective activities regarding any litigation or settlement thereof
           concerning the Patent Rights in the Field or Licensed Products or
           Licensed Processes; provided, however, that no settlement or consent
           judgement or other voluntary final disposition of any suit defended
           or action brought by a party pursuant to this Article 7 may be
           entered into without the consent of the other party, such consent not
           to be unreasonably withheld or delayed.

     7.8.  Tepha, during the period of this Agreement, shall have the sole right
           in accordance with the terms and conditions herein to sublicense any
           alleged infringer for future use of the Patent Rights in the Field.

8.   PRODUCT LIABILITY

     8.1.  INDEMNIFICATION. Tepha shall at all times during the term of this
           Agreement and thereafter, indemnify, defend and hold Metabolix and
           Monsanto, their directors, officers, employees and Affiliates,
           harmless against all claims and expenses, arising out of the death of
           or injury to any person or persons or out of any damage to property
           and against any other claim, proceeding, demand, expense and
           liability of any kind whatsoever resulting from or relating to the
           production, manufacture, sale, use, lease, consumption or
           advertisement of the Licensed Products and/or Licensed Process(es) *.

     8.2.  INSURANCE. Prior to the first use of a Licensed Product for humans,
           Tepha shall obtain and carry in full force and effect commercial,
           general liability insurance, including product liability insurance,
           which shall protect Tepha, Metabolix and Monsanto with respect to
           events covered by Paragraph 8.1 above. Such insurance shall be
           written by a reputable insurance company authorized to do business in
           the Commonwealth of Massachusetts, shall list Metabolix and Monsanto
           as additional named insured thereunder, shall be endorsed to include
           product liability coverage and shall require thirty (30) days written
           notice to be given to Metabolix prior to any cancellation or material
           change thereof. The limits of such insurance shall not be less than *
           per occurrence with an aggregate of * for personal injury including
           death; and * per occurrence with an aggregate of * for property
           damage. Tepha shall provide Metabolix with Certificates of Insurance
           evidencing the same. Tepha shall maintain such commercial general
           liability insurance during the period that any Licensed Product or
           Licensed Process is being used, distributed or sold and for six (6)
           years thereafter.

*    CONFIDENTIAL TREATMENT REQUESTED

                                        9

<Page>

9.   WARRANTIES AND DISCLAIMER

     9.1.  Metabolix warranty. Metabolix represents and warrants to Tepha that
           Metabolix *.

     9.2.  DISCLAIMER. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT: NEITHER
           PARTY, NOR THEIR RESPECTIVE DIRECTORS, OFFICERS, EMPLOYEES AND
           AFFILIATES MAKE ANY REPRESENTATIONS OR EXTEND ANY WARRANTIES OF ANY
           KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO
           WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE,
           VALIDITY OF PATENT RIGHTS CLAIMS, ISSUED OR PENDING, AND THE ABSENCE
           OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE. NOTHING IN
           THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION MADE OR
           WARRANTY GIVEN BY EITHER PARTY OR BY MONSANTO THAT THE PRACTICE OF
           THE LICENSES GRANTED HEREUNDER SHALL NOT INFRINGE THE PATENT RIGHTS
           OR OTHER INTELLECTUAL OR PROPRIETARY RIGHTS OF ANY THIRD PARTY.

10.  LIMITATION OF LIABILITY

     10.1. NO CONSEQUENTIAL DAMAGES. *, IN NO EVENT SHALL METABOLIX, TEPHA, OR
           THEIR RESPECTIVE DIRECTORS, OFFICERS, EMPLOYEES AND AFFILIATES BE
           LIABLE FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES OF ANY KIND, INCLUDING
           ECONOMIC DAMAGE OR INJURY TO PROPERTY AND LOST PROFITS, REGARDLESS OF
           WHETHER SUCH PARTY SHALL BE ADVISED, SHALL HAVE OTHER REASON TO KNOW,
           OR IN FACT SHALL KNOW OF THE POSSIBILITY OF THE FOREGOING.

11.  EXPORT CONTROLS

     11.1. Tepha acknowledges that it is subject to United States laws and
           regulations controlling the export of technical data, computer
           software, laboratory prototypes and other commodities (including the
           Arms Export Control Act, as amended and the United States Department
           of Commerce Export Administration Regulations). The transfer of such
           items may require a license from the cognizant agency of the United
           States Government and/or written assurances by Tepha that Tepha shall
           not export data or commodities to certain foreign countries without
           prior approval of such agency. Metabolix neither represents that a
           license shall not be required nor that, if required, it shall be
           issued.

12.  NON-USE OF NAMES

     12.1. Except as required by law or in raising funding, neither party shall
           use the names or trademarks of the other, nor any adaptation thereof,
           nor the names of any of the

*    CONFIDENTIAL TREATMENT REQUESTED

                                       10

<Page>

           other party's employees, in any advertising, promotional or sales
           literature without prior written consent obtained from such party, or
           said employee, in each case, such consent not to be unreasonably
           withheld, except that Tepha may state that it is licensed by
           Metabolix, under one or more of the patents and/or applications
           comprising the Patent Rights. Tepha may, however, use the name of any
           employee of Metabolix who is a consultant or member of an advisory
           board of Tepha, with their permission, and provided, also, that their
           affiliation with Metabolix is identified.

13.  DISPUTE RESOLUTION

     13.1. Except for the right of either party to apply to a court of competent
           jurisdiction for a temporary restraining order, a preliminary
           injunction or other equitable relief to preserve the status quo or to
           prevent irreparable harm, and except for any dispute relating to
           patent validity or infringement, any and all claims, disputes or
           controversies arising under, out of or in connection with the
           Agreement, shall be mediated in good faith. The party raising such
           dispute shall promptly advise the other party of such claim, dispute
           or controversy in a writing which describes in reasonable detail the
           nature of such dispute. If the parties by their senior management
           representatives shall be unable to resolve the dispute within thirty
           (30) days, then by no later than forty (40) business days after the
           recipient has received such notice of dispute, each party shall have
           selected for itself a representative who shall have the authority to
           bind such party, and shall additionally have advised the other party
           in writing of the name and title of such representative. By no later
           than sixty (60) business days after the date of such notice of
           dispute, such representatives shall schedule a date for a mediation
           hearing with the Cambridge Dispute Settlement Center or Endispute
           Inc. in Cambridge, Massachusetts or another mutually agreeable
           mediator. The parties shall enter into good faith mediation and shall
           share the costs equally. If the representatives of the parties have
           not been able to resolve the dispute within thirty (30) business days
           after such mediation hearing, the parties shall have the right to
           pursue any other remedies legally available to resolve such dispute
           in either the Courts of the Commonwealth of Massachusetts, or in the
           United States District Court for the District of Massachusetts, to
           whose jurisdiction for such purposes Metabolix and Tepha each hereby
           irrevocably consents and submits.

     13.2. Notwithstanding the foregoing, nothing in this Article shall be
           construed to waive any rights or timely performance of any
           obligations under this Agreement.

14.  CONFIDENTIALITY

     14.1. CONFIDENTIAL INFORMATION. Both Metabolix and TEPHA agree that all
           confidential information disclosed to the other party shall be deemed
           "Confidential Information" of the disclosing party. In particular,
           "Confidential Information" shall be deemed to include, but not be
           limited to, Know-How, Biological Materials, trade secrets,
           information, ideas, inventions, materials, samples, processes,
           procedures, methods, formulations, protocols, packaging designs and

*    CONFIDENTIAL TREATMENT REQUESTED

                                       11

<Page>

           materials, test data, future development plans, "Product" launch
           date, technological know-how and engineering, manufacturing,
           regulatory, marketing, servicing, sales, or financial matters
           relating to the disclosing party and its business.

     14.2. NONDISCLOSURE AND NONUSE. During the term and thereafter each
           receiving party: (i) shall maintain all Confidential Information in
           confidence; (ii) shall not disclose any Confidential Information to
           any third party without prior written consent of the disclosing party
           except that the receiving party may disclose in connection with
           consultants, subcontractors or agents or raising funding and
           technical development activities for purposes consistent with this
           Agreement pursuant to a written non-disclosure agreement with said
           parties, having terms of nondisclosure and nonuse at least as
           restrictive as those set forth herein; and (iii) shall use such
           Confidential Information only to the extent required to accomplish
           the purposes of this Agreement. A receiving party may disclose
           Confidential Information that is required to be disclosed pursuant to
           the law, by request of the FDA or other government authority or for
           medical or safety reasons, but only to the extent required to be
           disclosed by the FDA or other government authority. Both parties
           shall take precautions as each normally takes with its own
           confidential and proprietary information to prevent disclosure to
           third parties, but no less than reasonable precautions.

     14.3. EXCEPTIONS. Both parties agree that, notwithstanding the above, the
           obligations of confidentiality and nonuse shall not apply to:

           14.3.1 Information that at the time of disclosure is, or thereafter
                  becomes, generally known to the public, through no wrongful
                  act or failure to act on the part of the receiving party;

           14.3.2 Information that was known by or in the possession of the
                  receiving party at the time of receiving such information from
                  the disclosing party, as evidenced by written records;

           14.3.3 Information obtained by the receiving party from a third party
                  who is not breaching a commitment of confidentiality to the
                  disclosing party by revealing such information to the
                  receiving party, as evidenced by written records; or

           14.3.4 Information that is developed independently by the receiving
                  party without use of confidential information of the other
                  party, as evidenced by written records.

     14.4. Both Parties shall make diligent efforts to ensure that all
           employees, consultants, agents and subcontractors who may have access
           to Confidential Information of the other party, and any other third
           parties who might have access to Confidential Information, shall sign
           nondisclosure agreements consistent with the terms set forth in this
           Paragraph. No Confidential Information shall be disclosed to any
           employees, subcontractors, agents, consultants or third parties who
           do not have a need to receive such information for the purposes of
           this Agreement.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       12

<Page>

15.  TERMINATION

     15.1. TERMINATION BY METABOLIX. If Tepha shall cease to carry on its
           business, this Agreement shall terminate effective upon notice by
           Metabolix.

     15.2. TERMINATION FOR NONPAYMENT. Should Tepha fail to make any payment
           whatsoever due and payable to Metabolix hereunder, Metabolix shall
           have the right to terminate this Agreement effective on sixty (60)
           days' notice, unless Tepha shall make all such payments to Metabolix,
           within said sixty (60) day period. Upon the expiration of the sixty
           (60) day period, if Tepha shall not have made all such payments to
           Metabolix, the rights, privileges and license granted hereunder shall
           automatically terminate.

     15.3. TERMINATION FOR MATERIAL BREACH. Upon any material breach or default
           of this Agreement by Tepha, other than those occurrences set out in
           Paragraphs 15.1 and 15.2 hereinabove, which shall always take
           precedence in that order over any material breach or default referred
           to in this Paragraph 15.3, Metabolix shall have the right to
           terminate this Agreement and the rights, privileges and license
           granted hereunder effective on one hundred and twenty (120) days'
           notice to Tepha. Such termination shall become automatically
           effective unless Tepha shall have cured any such material breach or
           default prior to the expiration of the one hundred and twenty (120)
           day period. Upon any material breach or default of this Agreement by
           Metabolix, Tepha shall have the right to terminate this Agreement and
           the rights, privileges and license granted hereunder effective on one
           hundred and twenty (120) days' notice to Metabolix. Such termination
           shall become automatically effective unless Metabolix shall have
           cured any such material breach or default prior to the expiration of
           the one hundred and twenty (120) day period.

     15.4. TERMINATION BY TEPHA. Tepha shall have the right to terminate this
           Agreement at any time on six (6) months' notice to Metabolix, and
           upon payment of all amounts due Metabolix through the effective date
           of termination.

     15.5. DEFINITION OF EXPIRATION. For purposes of this Agreement, the term
           "expiration" shall mean expiration of the last to expire of the
           Patent Rights, and the co-terminus expiration of this Agreement,
           subject to the surviving licenses and provisions. The term
           "termination" shall mean termination of this Agreement prior to
           expiration in accordance with this Article 15.

     15.6. EFFECTS OF TERMINATION. Upon expiration or termination of this
           Agreement for any reason: (i) nothing herein shall be construed to
           release either party from any obligation that matured prior to
           expiration or the effective date of termination; (ii) Articles 1,
           2.4, 5.1 (for three (3) years), 7.1 (as to any infringement action
           instituted prior to termination), 8, 10, 13, 14, 16.4, 16.5, 16.6 and
           17 shall survive expiration or any termination; (iii) for a period of
           six (6) months after the effective date of termination, Tepha and its
           sublicensees may sell Licensed Products in inventory, and complete
           Licensed Products in the process of

*    CONFIDENTIAL TREATMENT REQUESTED

                                       13

<Page>

           manufacture at the time of such termination and sell the same,
           provided that Tepha shall pay the Running Royalties thereon as
           required by Article 3 of this Agreement and shall submit the reports
           required by Article 5 hereof on the sales of Licensed Products; (iv)
           if requested, each party shall immediately return all Confidential
           Information to the disclosing party and shall cease and refrain from
           any further use of such Confidential Information; (v) upon
           termination of this Agreement for any reason, any sublicense not then
           in default shall continue in full force and effect except that
           Metabolix shall be substituted in place of the Tepha, and Metabolix
           shall have no obligations under such sublicense beyond their
           obligations herein; (vi) upon termination (as defined in Paragraph
           15.5), if requested by Metabolix, Tepha shall return all Biological
           Materials and Know-How; and (vii) after expiration of this Agreement
           (as defined in Paragraph15.5), Tepha shall retain a perpetual,
           irrevocable, royalty-free, non-exclusive, transferable, worldwide
           license in the Field, with the right to sublicense, to use the
           Know-How.

     15.7. LICENSE TO METABOLIX. Upon termination of this Agreement for any
           reason (except expiration or termination by Tepha for breach by
           Metabolix under Paragraph 15.3), Tepha shall, grant and hereby grants
           Metabolix a nonexclusive license, with the right to sublicense, to
           all information then in Tepha's possession relevant to the
           commercialization of Licensed Products and/or Licensed Processes,
           including, but not limited to, research results, toxicology data,
           assays, preclinical data, prototypes, manufacturing processes
           including cell lines and unused, unexpired amounts of Licensed
           Products, clinical results, regulatory submissions, suppliers and
           customer lists. In such event Tepha shall receive a royalty equal to
           * of the gross amount of consideration, if any, subsequently received
           by Metabolix with respect to the Licensed Products and Licensed
           Processes.

16.  GENERAL

     16.1. INTEGRATED AGREEMENT. This Agreement (including its Appendices, which
           are incorporated herein by reference) constitutes the complete and
           exclusive statement of the agreement between the parties, and
           supersedes all prior agreements, proposals, negotiations and
           communications between the parties, both oral and written, regarding
           the subject matter hereof.

     16.2. WAIVER OR AMENDMENT. No waiver, alteration or amendment of any of the
           provisions of this Agreement shall be binding unless made in writing
           and signed by each of the parties hereto.

     16.3. NOTICES. Any payment, notice or other communication pursuant to this
           Agreement shall be sufficiently made or given on the date of mailing
           if sent to such party by certified first class mail, postage prepaid,
           return receipt requested addressed to it at its address below or as
           it shall designate by written notice given to the other party.

     If to Metabolix:

*    CONFIDENTIAL TREATMENT REQUESTED

                                       14

<Page>

           Metabolix, Inc.
           303 Third Street
           Cambridge, MA 02142
           Attn: President
           Fax: 617-492-1996

     If to Tepha:

           Tepha, Inc.
           303 Third Street
           Cambridge, MA 02142
           Attn: President
           Fax: 617-492-1996

     All such notices, if properly addressed, shall be effective when received.

     16.4. GOVERNING LAW. This Agreement shall be construed, governed,
           interpreted and applied in accordance with the laws of the
           Commonwealth of Massachusetts, without regard to conflict of laws
           principles, and as necessary the laws of the United States of
           America, except that questions affecting the construction and effect
           of any patent shall be determined by the law of the country in which
           the patent was granted. Each party agrees that venue for any dispute
           arising under this Agreement shall be Boston, Massachusetts, and
           waives any objection it has or may have in the future with respect to
           such venue.

     16.5. FAILURE TO EXERCISE REMEDY. If either party fails to enforce any term
           of this Agreement or fails to exercise any remedy, such failure to
           enforce or exercise on that occasion shall not prevent enforcement or
           exercise on any other occasion.

     16.6. NON-EXCLUSIVE RIGHTS. The rights and remedies of the parties provided
           in this Agreement shall not be exclusive and are in addition to any
           other rights and remedies available at law or in equity.

     16.7. ASSIGNMENT. Except as expressly provided in Article 2, neither party
           shall directly or indirectly sell, transfer, assign or delegate in
           whole or in part this Agreement, or any rights, duties, obligations
           or liabilities under this Agreement (collectively "assign"), by
           operation of law or otherwise, without the prior written consent of
           the other party, such consent not to be unreasonably withheld or
           delayed; provided, however, so long as the assignee shall not be a
           competitor of the other party, either party shall have the right to
           assign without consent all of its rights, duties, obligations and
           liabilities under this Agreement to any Affiliate or in connection
           with any sale, merger, consolidation, recapitalization or
           reorganization involving in each case the sale of all the capital
           stock of the party or all or substantially all of the assets of such
           party to which this Agreement relates. Subject to the foregoing, this
           Agreement shall inure to the benefit of and be binding upon the
           permitted successors and assigns of Metabolix and Tepha.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       15

<Page>

     16.8. INDEPENDENT CONTRACTORS. The parties agree that in the performance of
           this Agreement they are and shall be independent contractors. Nothing
           herein shall be construed to constitute either party as the agent of
           the other party for any purpose whatsoever, and neither party shall
           bind or attempt to bind the other party to any contract or the
           performance of any obligation or represent to any third party that it
           has any right to enter into any binding obligation on the other
           party's behalf.

     16.9. SEVERABILITY. The provisions of this Agreement are severable, and in
           the event that any provisions of this Agreement shall be determined
           to be invalid or unenforceable under any controlling body of the law,
           such invalidity or unenforceability shall not in any way affect the
           validity or enforceability of the remaining provisions hereof.

     16.10. COUNTERPARTS. This Agreement may be executed in one or more
           counterparts, each of which when executed shall be deemed to be an
           original but all of which taken together shall constitute one and the
           same agreement.

     16.11. PATENT MARKING. Tepha shall apply the patent marking notices
           required by the law of any country where Licensed Products are made,
           used, sold or imported.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       16

<Page>

     IN WITNESS WHEREOF, the parties have duly executed this Agreement the day
and year set forth below.

Metabolix, Inc.                         Tepha, Inc.

By: /s/ Oliver P. Peoples               By: /s/ Simon F. Williams
    ---------------------------------       ------------------------------------
Name: Oliver P. Peoples                 Name: Simon F. Williams
Title: Vice President R & D             Title: President
Date: September 9, 2003                 Date: September 9, 2003

*    CONFIDENTIAL TREATMENT REQUESTED

                                       17<Page>

WHENEVER CONFIDENTIAL INFORMATION IS OMITTED HEREIN (SUCH OMISSIONS ARE DENOTED
BY AN ASTERISK*), SUCH CONFIDENTIAL INFORMATION HAS BEEN SUBMITTED SEPARATELY TO
THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT.

                    TECHNOLOGY ALLIANCE AND OPTION AGREEMENT

     This Technology Alliance and Option Agreement (the "Agreement") dated as of
November 4, 2004 (the "Effective Date") is by and between ADM Polymer
Corporation, a corporation duly incorporated and validly existing under the laws
of the State of Delaware, with headquarters located at 4666 Faries Parkway,
Decatur, IL 62526 ("ADM Sub"), and Metabolix, Inc., a corporation duly
incorporated and validly existing under the laws of the State of Delaware, with
headquarters located at 21 Erie Street, Cambridge, MA 02139-4260 ("MBX") (MBX
and ADM Sub are collectively the "Parties" and each is a "Party").

                                    RECITALS

     WHEREAS, MBX has developed technology relating to the fermentation,
recovery and formulation of PHA Material (as defined below) and possesses
patents, trade secrets and other intellectual property rights in relation
thereto;

     WHEREAS, MBX is seeking a collaborator to participate, in the continued
commercialization of the PHA Material;

     WHEREAS, ADM Sub has capabilities and resources relating to the
fermentation of PHA Materials and desires to employ the MBX technology in
commercial scale reactors too confirm performance parameters and potential
manufacturing economics;

     WHEREAS, ADM Sub is a wholly owned subsidiary of Archer-Daniels-Midland
Company ("ADM"); and

     WHEREAS, ADM Sub and MBX desire to enter into an agreement under which the
two Parties would cooperate in the preparation of certain hatches of PHA
Material and under which MBX would grant to ADM Sub the option to enter into a
commercial alliance to further commercialize the PHA Material, all on the terms
and conditions set forth herein.

     NOW, THEREFORE, in consideration of the recitals and the mutual covenants
and promises contained herein, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Parties hereto
do hereby agree as follows.

                                    ARTICLE 1
                                   DEFINITIONS

     "ADM SUB BACKGROUND TECHNOLOGY" means any Technology used by ADM Sub, or
provided by ADM Sub for use, in the Technology Alliance Program that is
Controlled by ADM Sub: (a) as of the Effective Date, or (b) developed, conceived
or reduced to practice solely by employees of, or consultants to, ADM Sub or its
Affiliates in the conduct of activities outside the Technology Alliance Program,
without the material use of any MBA Technology or Program Technology.

*    CONFIDENTIAL TREATMENT REQUESTED

<Page>

     "ADM SUB CONSTRUCTION MASTER PLAN AND BUDGET" shall have the meaning set
forth in Section 3.1.

     "ADM SUB MANUFACTURING FACILITY" means an ADM Sub facility designed to
produce, through microbial fermentation, approximately fifty thousand (50,000)
tons of PHA Material, having an acceptable level of purity, during each twelve
(12) month period, on an ongoing basis through a stable and robust operation,
over a period of years.

     "ADM SUB PATENT RIGHTS" means any Patent Rights Controlled by ADM Sub and
claiming or covering the ADM Sub Technology.

     "ADM SUB PROGRAM TECHNOLOGY" means any Technology developed, conceived or
reduced to practice solely by employees of, or consultants to, ADM Sub or its
Affiliates (alone or jointly with a third party) during the course of
performance of the Technology Alliance Program, with or without the material use
of any MBX Technology or Program Technology. Nothing in this definition shall be
construed as conveying any rights on ADM Sub to practice any MBX Technology
after the Term.

     "ADM SUB PROPRIETARY MATERIALS" means any Proprietary Materials Controlled
by ADM Sub and used by ADM Sub, provided by ADM Sub for use, or necessary or
useful in the Technology Alliance Program.

     "ADM SUB TECHNOLOGY" means, collectively, ADM Sub Proprietary Materials,
ADM Sub Background Technology and ADM Sub Program Technology.

     "AFFILIATE" of a Person means any other Person that directly, or indirectly
through one or more intermediaries, controls, is controlled by or is under
common control with such Person. "Control" and, with correlative meanings, the
terms "controlled by" and "under common control with" shall mean the power to
direct or cause the direction of the management or policies of a Person, whether
through the ownership of voting securities, by contract, resolution, regulation
or otherwise. Tepha, Inc. is hereby deemed not to be an Affiliate of MBX.

     "COMMERCIAL ALLIANCE" shall have the meaning set forth in the Commercial
Alliance Agreement.

     "COMMERCIAL ALLIANCE AGREEMENTS" means the agreements titled "Commercial
Alliance Agreement," "Manufacturing Agreement," "Formulation Agreement,"
"Operating Agreement," "ADM Sub Services Agreement," "MBX Services Agreement,"
and "Loan and Security Agreement" attached hereto as EXHIBIT A to be executed
and delivered by the parties indicated therein upon the exercise of the Option
by ADM Sub in accordance with the terms of this Agreement.

     "COMMERCIALLY REASONABLE EFFORTS" shall mean, with respect to the efforts
to be applied by a Party in performing a referenced obligation hereunder, the
amount and quality of effort and resources that would be applied by a reasonable
manager or management team at a corporation having comparable expertise and
assets as such Party, to accomplish a task or to perform an obligation having
comparable relative importance to the success or failure of a commercial
enterprise that is comparable to the Commercial Alliance. For purposes of this
definition, a

*    CONFIDENTIAL TREATMENT REQUESTED

                                       2

<Page>

commercial enterprise would be comparable to the Commercial Alliance if it poses
similar anticipated technical and business risks or challenges and similar
anticipated Financial return to the Parties as measured at the time of the
expenditure of the effort. When ADM Sub has an obligation to use "Commercially
Reasonable Efforts" herein, the following shall apply: (i) the term
"Commercially Reasonable Efforts" shall be defined as it is in this definition
but by reference to ADM Sub and ADM as if they were a single entity and (ii) in
determining whether ADM Sub has satisfied its obligation, the efforts applied by
and ADM Sub and ADM shall both be taken fully into account.

     "CONFIDENTIAL INFORMATION" means: (a) all tangible embodiments of
Technology produced or discovered by a Party, or jointly by one or more Parties
under the Technology Alliance Program, and all information concerning the terms
of this Agreement, and (b) with respect to a Party (the "Receiving Party"), all
information, Technology and Proprietary Materials which are disclosed by another
Party (the "Disclosing Party") to the Receiving Party hereunder or to any of its
employees, consultants, or Affiliates; except to the extent that the
information, (i) as of the date of disclosure is demonstrably known to the
Receiving Party or its Affiliates, as shown by written documentation, other than
by virtue of a prior confidential disclosure to such Party or its Affiliates;
(ii) as of the date of disclosure is in, or subsequently enters, the public
domain, through no fault or omission of the Receiving Party, or any of its
Affiliates; (iii) is obtained from a third party having a lawful right to make
such disclosure free from any obligation of confidentiality to the Disclosing
Party; or (iv) is independently developed by or for the Receiving Party without
reference to or reliance upon any Confidential Information of the Disclosing
Party as demonstrated by competent written records.

     "CONSTRUCTION" AND "CONSTRUCT" shall mean, in respect to a building, the
activities, and their performance, that are usual and appropriate to create a
completed facility that: (i) is in all material respects in compliance with all
material safety, health, zoning, environmental and other regulations and laws
applicable to it whether such applicability is based on its location, physical
dimensions and attributes, its intended uses or otherwise and (ii) is designed
to enable and support state-of-the-art operations pertaining to its intended
purpose. The terms "Construction" and "Construct" shall include the following
activities and their performance with respect to a facility: planning,
designing, engineering, construction, procurement, equipping and acquiring the
necessary permits.

     "CONSTRUCTION COSTS" are those costs and expenses that are included in the
ADM Sub Construction Master Plan and Budget as approved by the TAC in accordance
with Section 3.2.5 to the extent actually incurred by ADM Sub in the
Construction of the ADM Sub Manufacturing Facility.

     "CONTROL" OR "CONTROLLED" means (a) with respect to Technology (other than
Proprietary Materials) or Patent Rights, the possession by a Party of the
ability to grant a license or sublicense to such Technology or Patent Rights as
provided herein without violating the terms of any agreement or arrangement
between such Party and any third party, and (b) with respect to Proprietary
Materials, the possession by a Party of the ability to supply such Proprietary
Materials to the other Party for use as provided herein without violating the
terms of any agreement or arrangement between the supplying Party and any third
party.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       3

<Page>

     "EFFECTIVE DATE" means the date first above written.

     "FERMENTATION PERFORMANCE PARAMETERS" means the various parameters for
production of PHA Cell Paste through fermentation at the * scale and the * scale
as set forth on EXHIBIT B.

     "FIELD" means the research, development, manufacture, use, sale and
importation of PHA Material and PHA Formulations; provided that the Field shall
not include any uses that are within the "Field of Use" as that term is defined
in the License Agreement by and between MBX and Tepha, Inc. dated October 1,
1999.

     "GOAL" shall have the meaning set forth in Section 3.1.

     "JOINT PROGRAM TECHNOLOGY" means Technology developed, conceived or reduced
to practice jointly by employees of, or consultants to, the Parties (with or
without a third party) during the course of performance of the Technology
Alliance Program. Nothing in this definition shall be construed as conveying any
rights on ADM or ADM Sub to practice any MBX Technology after the Term. Nothing
in this definition shall be construed as conveying any rights on MBX to practice
any ADM Sub Technology after the term.

     "JOINT SALES COMPANY" shall have the meaning set forth in the Commercial
Alliance Agreement.

     "KNOWLEDGE" means, with respect to MBX, the actual knowledge and awareness,
without the requirement of investigation, of any of the following four (4)
members of MBX management: President and CEO, Chief Scientific Officer, Chief
Financial Officer and Director of Manufacturing and Development, without the
requirement of investigation, and, with respect to ADM Sub, the actual knowledge
and awareness, without the requirement of investigation, of any of the following
nine (9) members of ADM management: Senior Vice President (Corn Processing and
Food Specialties) (John D. Rice), President of Natural Health & Nutrition
Division (Steven J. Furcich), Assistant Controller (Marc A. Sanner), Corporate
Counsel Intellectual Property (Brian R. Leslie), Senior Attorney (Bradley E.
Riley), Senior Vice President Venture Research (Mark G. Matlock), Vice President
Technology Assessment (Terry A. Stoa), President of ADM Research Division
(Thomas P. Binder), and Vice President of Research, Molecular Biology -
Fermentation (Leif P. Solheim).

     "MANUFACTURING COST" shall mean the costs incurred by ADM Sub in
manufacturing and packaging the Marketing Material as specified in EXHIBIT C,
calculated and payable in the manner set forth in this Agreement.

     "MARKETING MATERIAL" shall have the meaning set forth in Section 3.3.

     "MBX APPLICATIONS PATENT RIGHTS" means any Patent Rights Controlled by MBX
that claim or cover specific uses, within the Field, of PHA Materials or PHA
Formulations.

     "MBX BACKGROUND TECHNOLOGY" means any Technology used by MBX, or provided
by MBX for use, in the Technology Alliance Program that is Controlled by MBX:
(a) as of the Effective Date, or (b) developed, conceived or reduced to practice
solely by employees of, or

*    CONFIDENTIAL TREATMENT REQUESTED

                                       4

<Page>

consultants to, MBX or its Affiliates in the conduct of activities outside the
Technology Alliance Program, without the material use of any ADM Sub Technology
or Program Technology.

     "MBX PATENT RIGHTS" means any Patent Rights Controlled by MBX and claiming
or covering the MBX Technology, including without limitation the MBX
Applications Patent Rights.

     "MBX PROGRAM TECHNOLOGY" means any Technology developed; conceived or
reduced to practice solely by employees of, or consultants to, MBX or its
Affiliates (alone or jointly with a third party) during the course of
performance of the Technology Alliance Program, with or without the material use
of any ADM Sub Technology or Program Technology.

     "MBX PROPRIETARY MATERIALS" means any Proprietary Materials Controlled by
MBX and used by MBX, provided by MBX for use, or necessary or useful in the
Technology Alliance Program. MBX Proprietary Materials shall include, without
limitation, all PHA Material and PHA Formulations supplied as samples to ADM
Sub, all cell lines (including all master stocks and working stock whether
prepared by ADM Sub or MBX) and all fermentation media, supplied by MBX to ADM
Sub, and all progeny, derivatives and mutated forms developed therefrom.

     "MBX TECHNOLOGY" means, collectively, MBX Proprietary Materials, MBX
Background Technology and MBX Program Technology.

     "OPTION" shall have the meaning set forth in Section 4.3 hereof.

     "PATENT RIGHTS" means the rights and interests in and to issued patents and
pending patent applications (which for purposes of this Agreement shall be
deemed to include certificates of inventions and applications for certificates
of invention and priority rights) in any country, including all provisional
applications, substitutions, continuations, continuations-in-part, divisionals,
and renewals, all letters patent granted thereon, and all reissues,
reexaminations and extensions thereof Controlled by a Party.

     "PERMITTED ACTIVITIES" shall have the meaning set forth in Section 6.1.

     "PERSON" means any individual, partnership (whether general or limited),
limited liability company, corporation, trust, estate, association, nominee or
other entity.

     "PHA CELL PASTE" means the paste, containing the PHA Material, recovered
from whole fermentation broth and meeting the specifications set forth in
EXHIBIT D.

     "PHA FORMULATIONS" means PHA Material that has been processed by blending
different types of PHA Material together with other polymers and/or with other
additives, including nucleants, clarifiers, flow modifiers, plasticizers, flame
retardants and heat stabilizers.

     "PHA KNOW-HOW MATERIAL" means PHA Material, the manufacture, use, sale or
importation of which is accomplished or performed with the use of the MBX
Technology or Joint Program Technology.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       5

<Page>

     "PHA MATERIAL" means the following forms of polyhydroxyalkanoate: *, when
produced by any means other than via Plants, and any other forms of
polyhydroxyalkanoate, produced by any means other than via Plants, that are
substitutable by any customer with one or more of the above substances, are
generally technically and commercially feasible in the marketplace, and have a
potential adverse affect on the sales or profitability of the Joint Sales
Company in a material way. For avoidance of doubt, any PHB copolymers having at
least fifty percent (50%) of the *, when produced by any means other than via
Plants, are hereby deemed to be included in the definition of PHA Material.

     "PHA PATENTED MATERIAL" means PHA Material, the manufacture, use, sale or
importation of which within or into the United States by a Person other than
MBX, absent the licenses granted herein, would infringe a Valid Claim of the MBX
Patent Rights or a Valid Claim within Patent Rights claiming or covering any
Technology within the Joint Program Technology.

     "PHA RELATED MATERIALS" means any polymer material consisting of one or
more hydroxyacids of the general formula: *

     "PHA SUPPLEMENTAL KNOW HOW MATERIAL" means PHA Material, the manufacture,
use, sale or importation of which is accomplished or performed with the use of a
cell Line Controlled by MBX and delivered by MBX to ADM Sub at any time during
the Term.

     "PLANTS" shall mean photosynthetic organisms when not raised through
fermentation, but in any case excluding * For avoidance of doubt, * is included
within the definition of Plants.

     "PROGRAM TECHNOLOGY" means ADM Sub Program Technology, Joint Program
Technology and MBX Program Technology.

     "PROPRIETARY MATERIALS" means any tangible chemical, biological or physical
research materials that are furnished by or on behalf of one Party to the other
Party (the "Receiving Party") in connection with this Agreement, regardless of
whether such materials are specifically designated as proprietary by the
transferring Party, except to the extent that the materials, (i) are already in
the possession of the Receiving Party or its Affiliates, as shown by written
documentation, other than by virtue of a prior delivery of such materials to the
Receiving Party or its Affiliates from the other Party or one of its Affiliates
subject to confidentiality obligations; (ii) as of the date of disclosure is in
the public domain (without restriction on use or availability), or subsequently
enters the public domain (without restriction on use or availability) through no
fault or omission of the Receiving Party or any of its Affiliates; (iii) is
obtained from a third party having a lawful right to provide such material free
from any restriction on use; or (iv) is independently developed by or for the
Receiving Party without reference to or reliance upon any Proprietary Materials
of the Disclosing Party as demonstrated by clear and convincing evidence.

     "RECOVERY PERFORMANCE PARAMETERS" shall mean the various parameters for
performance of recovery of PHA Material from PHA Cell Paste as set forth on
EXHIBIT E.

     "ROYALTY TERM" means that period commencing upon the * and continuing until
the later of the expiration or termination of * from the Effective Date.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       6

<Page>

     "SENIOR EXECUTIVES" shall have the meaning set forth in Section 11.3.1.

     "SUPPLEMENTAL ROYALTY TERM" means that period commencing upon the delivery
by MBX to ADM or ADM Sub of a cell line Controlled by MBX used in the production
or manufacture of PHA Supplemental Know How Material and ending upon the * to
occur of (i) the *, and (ii) * from the date of such delivery.

     "TECHNICAL ASPECTS OF THE GOAL" shall have the meaning set forth in Section
3.1.

     "TECHNOLOGY" means and includes all inventions, discoveries, improvements,
trade secrets, know-how and proprietary methods and Proprietary Materials,
whether or not patentable.

     "TECHNOLOGY ALLIANCE COMMITTEE" or "TAC" shall have the meaning set forth
in Section 2.1.

     "TECHNOLOGY ALLIANCE OUTPUT" shall have the meaning set forth in Section
3.3.

     "TECHNOLOGY ALLIANCE PLAN" shall mean the detailed plan for conducting the
Technology Alliance Program attached hereto as EXHIBIT F, subject to such
additions and amendments as the TAC shall determine in accordance with Section
2.1.1.

     "TECHNOLOGY ALLIANCE PROGRAM" shall mean the research, development and
evaluative activities to be conducts by the Parties as set forth herein, and in
the Technology Alliance Plan.

     "TECHNOLOGY TRANSFER" shall have the meaning set forth in Section 3.2.2.

     "THIRD PARTY IP ROYALTY OFFSET" shall have the meaning set forth in Section
8.4.2(b).

     "VALID CLAIM" means a claim within a patent application or patent that has
not been abandoned or finally determined to be unenforceable or invalid by a
court or administrative agency with competent jurisdiction where all appeal
rights have been exhausted or expired.

                                    ARTICLE 2
                    ADMINISTRATION OF THE TECHNOLOGY ALLIANCE

     2.1 TECHNOLOGY ALLIANCE COMMITTEE. MBX and ADM Sub shall establish a
Technology Alliance Committee (the "Technology Alliance Committee" or "TAC") to
plan and oversee the execution of the Technology Alliance Program.

          2.1.1 RESPONSIBILITIES OF TAC. The TAC shall review and oversee the
progress of the Technology Alliance Program and recommend necessary amendments
to the Technology Alliance Plan prior to its initial implementation and also
during the conduct of the Technology Alliance Program. The TAC shall review and
approve the ADM Sub Construction Master Plan and Budget.

          2.1.2 MEMBERSHIP OF TAC. Each Party shall appoint three (3) members to
the TAC one of which shall be designated as its "Co-Chair." Each Party shall
have the right at any

*    CONFIDENTIAL TREATMENT REQUESTED

                                       7

<Page>

time to substitute individuals, on a permanent or temporary basis, for any of
its previously designated representatives to the TAC, including its Co-Chair, by
giving written notice thereof to the other Party. Initial designees of ADM Sub
and MBX to the TAC shall be as set forth on Exhibit G.

     2.2 MEETINGS.

          2.2.1 SCHEDULE OF MEETINGS. The TAC shall establish a schedule of
times for its meetings, taking into account, without limitation, the planning
needs of the Technology Alliance Program. The TAC shall meet monthly unless
otherwise agreed upon by the Parties. Meetings shall also be convened upon the
determination of either or both of the Co-Chairs of the TAC by written notice
(including notice via e-mail) thereof to their respective members that a meeting
is required to discuss or resolve any matter or matters with respect to the
Technology Alliance Program. Meetings shall alternate between the respective
offices of the Parties or another mutually agreed upon location; provided,
however, that the Parties may mutually agree to meet by teleconference or video
conference or may act by a written, memorandum signed by the Co-Chairs of the
TAC.

          2.2.2 QUORUM; VOTING; DECISIONS. At each meeting of the TAC, the
participation of at least one member designated by each of the Parties shall
constitute a quorum. Each TAC member shall have one vote on all matters before
the TAC; provided, however, that the member or members of each of the Parties
present at any meeting shall have the authority to cast the votes of any of such
Party's members who are absent from the meeting. All decisions of the TAC shall
be made by majority vote of all of the members, with at least one representative
from each of the Parties voting with the majority. Whenever any action by the
TAC is called for hereunder during a time period in which a meeting is not
scheduled, the Co-Chairs shall cause the TAC to take the action in the requested
time period by calling a special meeting or by action without a formal meeting
by written memorandum signed by both Co-Chairs of the TAC. Representatives of
each Party or of its Affiliates, in addition to the members of the TAC, may
attend meetings as non-voting observers at the invitation of either Party with
prior notice to the other Party. In the event that the TAC is unable to resolve
any matter before it, such matter shall be resolved as set forth in Section 11.3
hereof.

          2.2.3 MINUTES. A secretary shall be appointed to keep accurate minutes
of the deliberations of the TAC recording all proposed decisions and all actions
recommended or taken. Drafts of such minutes shall be delivered to the Co-Chairs
of the TAC within a reasonable period of time not to exceed five (5) days after
a TAC meeting. Draft minutes shall be edited by the Parties and shall be issued
in final form within a reasonable time not to exceed ten (10) days after the
meeting only with their approval and agreement as evidenced by their signatures
on the minutes.

          2.2.4 EXPENSES. MBX and ADM Sub shall each bear all expenses of their
respective TAC members related to their participation on the TAC and attendance
at TAC meetings.

     2.3 DECISION-MAKING RESPONSIBILITIES. The TAC shall be solely responsible
for making all decisions relating to planning and overseeing the execution of
the Technology

*    CONFIDENTIAL TREATMENT REQUESTED

                                       8

<Page>

Alliance Program that are not specifically reserved to a Party hereunder. All
such decisions shall be made in good faith with he objective, using Commercially
Reasonable Efforts, of achieving the Goal.

                                    ARTICLE 3
                           TECHNOLOGY ALLIANCE PROGRAM

     3.1 GOAL OF TECHNOLOGY ALLIANCE PROGRAM. The goal of the Technology
Alliance Program is to (i) produce PHA Cell Paste, first in a fermenter having a
capacity of approximately * and then in a fermenter having a capacity of
approximately *, in both cases, in a manner and with results that meet the
applicable Fermentation Performance Parameters; (ii) demonstrate recovery of PHA
Material in a manner and with results that meet the Recovery Performance
Parameters (the items listed in the foregoing "(i)" and "(ii)" collectively are
the "Technical Aspects of the Goal"); and (iii) based upon the results of (i)
and (ii) above, have ADM Sub develop and the TAC agree upon a completed master
plan for Construction of the ADM Sub Manufacturing Facility, including without
limitation, surveys, blueprints, and engineering studies, which master plan
shall be organized into a detailed, multiphase process for undertaking and
completing Construction of the ADM Sub Manufacturing Facility and which shall
have a project budget with projected detailed expenditures provided for each
phase of the Construction process, all of which shall be in form and substance,
suitable for ADM Sub's management and board of directors to make a determination
to approve the expenditures for the ADM Sub Manufacturing Facility as and to the
extent required by ADM Sub's corporate governance polices and procedures (the
"ADM Sub Construction Master Plan and Budget") (collectively the "Goal").
Successful completion of the Goal is intended to confirm the potential economics
of producing PHA Material at commercial scale as part of a long-term commercial
alliance.

     3.2 CONDUCT OF TECHNOLOGY ALLIANCE PROGRAM. The Parties shall use
Commercially Reasonable Efforts to perform their respective obligations under
the Technology Alliance Program, in accordance with the provisions herein and
the provisions set forth in the Technology Alliance Plan, including without
limitation, the timelines for performance.

          3.2.1 CERTAIN MUTUAL REPRESENTATIONS. The Parties hereby represent and
warrant to each other as follows: (i) it shall use Commercially Reasonable
Efforts to perform its obligations under the Technology Alliance Plan in
accordance with high scientific and engineering principles and procedures, and
that it shall perform such obligations in compliance in all material respects
with all requirements of applicable laws, rules, and regulations, (ii) it shall
use Commercially Reasonable Efforts to achieve the objectives of the Technology
Alliance Program efficiently and expeditiously and (iii) it shall proceed
diligently with the Technology Alliance Program using Commercially Reasonable
Efforts, including allocating time, effort, equipment, and skilled personnel to
attempt to complete the Technology Alliance Program and achieve the Goal
successfully and promptly.

          3.2.2 TECHNOLOGY TRANSFER. Promptly upon execution of this Agreement,
but in mo event later than three (3) months from the Effective Date, MBX and ADM
Sub shall use Commercially Reasonable Efforts to conduct a transfer of MBX
Technology to ADM Sub: (i) as set forth in the Technology Alliance Plan and (ii)
as and

*    CONFIDENTIAL TREATMENT REQUESTED

                                       9

<Page>

to the extent reasonably necessary to enable ADM Sub to produce PHA Cell Paste
(the "Technology Transfer"). MBX and ADM Sub shall each devote Commercially
Reasonable Efforts, including devoting personnel and other resources, to
complete the Technology Transfer in accordance with the requirements, including
without limitation the schedule set forth in the Technology Alliance Plan;
provided, MBX shall have no obligation to transfer any Proprietary Materials or
Technology that MBX does not Control as part of the Technology Transfer. ADM Sub
acknowledges that some of the MBX Technology that will be transferred to ADM Sub
is in the form of trade secrets. In an effort to ensure the maximum continued
protection of MBX's rights in such trade secrets, and in keeping with Article 7
hereof ADM Sub covenants that it will provide access to the MBX Technology only
to employees of ADM and ADM Sub who have a need to have access to such MBX
Technology in order to complete the Technology Transfer and perform ADM Sub's
obligations under the Technology Alliance Plan. MBX acknowledges that some of
the ADM Sub Technology that may be transferred to MBX is in the form of trade
secrets. In an effort to ensure e maximum continued protection of ADM Sub's
rights in such trade secrets, and in keeping with Article 7 hereof, MBX
covenants that it will provide access to the ADM Sub Technology only to
employees of MBX who have a need to have access to such ADM Sub Technology in
order to perform MBX's obligations under the Technology Alliance Plan.

          3.2.3 FERMENTATION OPERATION. ADM Sub shall use Commercially
Reasonable Efforts, including making available personnel, plant, equipment and
other resources, to produce the PHA Cell Paste in the quantities, form and
condition set forth in the Technology Alliance Plan. Such resources shall be
made available for the Technology Alliance Program in the manner and to the
extent set forth herein and in the Technology Alliance Plan, with the purpose of
achieving the Goal. MBX shall have reasonable access to that portion, of the
facilities at which such production operations are conducted as is reasonably
necessary to observe and participate in such operations. MBX acknowledges that
the personnel, plant, equipment and other resources utilized in producing the
PHA Cell Paste will not be dedicated to such purpose solely, and ADM Sub will
put such resources to other uses during the Technology Alliance Program, in a
manner consistent with ADM Sub's ability to perform its obligations as described
herein and in the Technology Alliance Plan. At the request of either Party, the
TAC will, within ten (10) days after such request, determine whether the Parties
have, as of that date; successfully produced PHA Cell Paste, in a fomenter
having a capacity of approximately *, in a manner and with results that meet the
applicable Fermentation Performance Parameters.

          3.2.4 RECOVERY OPERATION. MBX shall use Commercially Reasonable
Efforts, including making available personnel, plant, equipment and other
resources, to demonstrate recovery of PHA Material as set forth in the
Technology Alliance Plan. Such resources shall be made available for the
Technology Alliance Program in the manner and to the extent set forth herein and
in the Technology Alliance Plan, with the purpose of achieving the Goal. ADM and
ADM Sub shall have reasonable access to that portion of the MBX facilities, or
facilities of third panics, at which such production operations are conducted as
is reasonably necessary to observe and participate in such operations. ADM Sub
acknowledges that the personnel, plant, equipment and other resources utilized
to perform the recovery of PHA Material will not be dedicated to such purpose
solely, and MBX will put such resources to other uses during the Technology
Alliance Program, in a manner consistent with MBX's ability to perform its
obligations as

*    CONFIDENTIAL TREATMENT REQUESTED

                                       10

<Page>

described herein and in the Technology Alliance Plan. At the request of either
Party, the TAC will, within ten (10) days after such request, determine whether
the Parties have, as of that date, successfully demonstrated the recovery of PHA
Material in a manner and with results that meet the Recovery Performance
Parameters.

          3.2.5 ADM SUB CONSTRUCTION MASTER PLAN AND BUDGET. ADM Sub shall
prepare the ADM Sub Construction Master Plan and Budget, with the assistance of
MBX and in consultation with any Third Party Consultants as shall be approved by
the TAC. After the completion of the ADM Sub Construction Master Plan and
Budget, the TAC will promptly conduct a complete review of such document, and
shall designate and approve those items or categories of costs and expenses
provided in such documents as Construction Costs and shall indicate whether and
why certain items or categories of costs and expenses do not qualify as
Construction Costs, in whole or in part, and whether such costs and expenses
could so qualify under other circumstances, for example, if more information
were provided as the necessity and reasonableness of the particular costs and
expenses or the features or facilities to which such costs and expenses relate.
After such review and approval process is completed by the TAC, in the event ADM
Sub desires to strike the Option, ADM Sub shall seek all approvals and
authorizations required under its corporate governance policies and practices to
authorize the Construction of the ADM Sub Manufacturing Facility including the
authorization to expend the amounts provided for in the ADM Sub Construction
Master Plan and Budget.

     3.3 OUTPUT FROM TECHNOLOGY ALLIANCE PROGRAM. ADM Sub will use Commercially
Reasonable Efforts to produce PHA Cell Paste in such amounts as result from the
operations set forth in the Technology Alliance Plan (the "Technology Alliance
Output") and such additional amounts as the Parties may agree to in writing (the
"Marketing Material") for use by MBX in developing the market for PHA Material.
The Technology Alliance Output and the Marketing Material will be made available
by ADM Sub to MBX as set forth in this Section 3.3.

          3.3.1 ANALYSIS OF TECHNOLOGY ALLIANCE OUTPUT. MBX will use the
Technology Alliance Output to demonstrate recovery of PHA Material in accordance
with Section 3.2.4 and the Technology Alliance Plan. Further, the Technology
Alliance Output will be used by the Parties to perform such evaluation and
analysis as is necessary or useful in determining whether the Parties have
achieved the Goal. Without limiting the foregoing statement, the Technology
Alliance Output will be evaluated and analyzed by the Parties, in accordance
with the procedures and methods set forth in the Technology Alliance Plan, to
determine whether the Technology Alliance Output meets the Fermentation
Performance Parameters and the Recovery Performance Parameters.

          3.3.2 PURCHASE OF TECHNOLOGY ALLIANCE OUTPUT BY MBX. MBX shall have
the right, but not the obligation, to purchase the Technology Alliance Output
from ADM Sub at a price of * of PHA Material contained within the PHA Cell
Paste, on a one hundred percent (100%) purity basis, and the right and
obligation to purchase the Marketing Material manufactured in accordance with
the applicable agreement between the Parties, from ADM Sub, at ADM Sub's
Manufacturing Cost, F.O.B. Decatur, Illinois. MBX may exercise this purchase
option at any time, and from time-to-time, during the Technology Alliance
Program and up to thirty (30) days after the expiration or termination of the
Technology Alliance Program, by written notice to ADM Sub, stating its desire to
purchase, the quantity to be purchased (up to the

*    CONFIDENTIAL TREATMENT REQUESTED

                                       11

<Page>

total amount that is then available) and shipping and delivery instructions. ADM
Sub shall invoice MBX for amounts so purchased no sooner than at the time of
delivery and the purchase price for amounts ordered and delivered in accordance
herewith shall be payable by MBX within thirty (30) days of receipt of an
invoice from ADM Sub by wire transfer of immediately available fluids to an
account in the United States designated by ADM Sub. Technology Alliance Output
and Marketing Material purchased hereunder shall be purchased "as is," without
warranty of any kind other than that the Technology Alliance Output and
Marketing Material shall have been stored and handled, from the time of
production until the delivery to MBX, in accordance with the requirements of the
Technology Alliance Plan or as otherwise agreed by the Parties. Technology
Alliance Output and Marketing Material purchased by MBX shall be used by MBX for
performing its obligations pursuant to this Agreement and for market development
activities benefiting the Parties and the potential Commercial Alliance between
them. Technology Alliance Output that is not purchased by MBX shall be used by
ADM Sub solely for internal research and development purposes, or if not soused,
ADM Sub shall either store (for later sale to MBX or the Joint Sales Company or
for later use by ADM Sub solely for internal research purposes) or dispose of
the unused Technology Alliance Output, at ADM Sub's option.

     3.4 REPORTING REQUIREMENTS. Within ten (10) days after the end of each
month during the term of the Technology Alliance Program, or as otherwise agreed
to by the Parties, the Parties shall provide each other with a written progress
report which shall describe the activities that have been performed to date in
connection with the Technology Alliance Program, including without limitation,
an evaluation of the work performed in relation to the Goal of the Technology
Alliance Program, and will provide such other information as may be required by
the Technology Alliance Plan or reasonably requested by MBX or ADM Sub.

     3.5 RECORDS. ADM Sub and MBX shall maintain records with respect to the
Technology Alliance Program in sufficient detail and in a good scientific manner
appropriate to support patent filings, which shall be complete and accurate and
shall fully and properly reflect all work done and results achieved in the
performance of the Technology Alliance Program. All such records shall be
retained for at least five (5) years after the termination of this Agreement, or
for such longer period as may be required by applicable law. Each of ADM Sub and
MBX shall have the right, during normal business hours and upon reasonable
notice, to inspect and copy any such records that are maintained hereunder.

                                    ARTICLE 4
                              INTELLECTUAL PROPERTY

     4.1 OWNERSHIP.

          4.1.1 BACKGROUND TECHNOLOGY, PROPRIETARY MATERIALS. Subject to the
rights and licenses granted herein, ADM Sub shall own all right, title and
interest in and to any: (i) ADM Sub Background Technology, (ii) ADM Sub Program
Technology and (iii) ADM Sub Proprietary Materials. Subject to the rights and
licenses granted herein, MBX shall own all right, title and interest in and to
any: (x) MBX Background Technology, (y) MBX Program Technology and (z) MBX
Proprietary Materials.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       12

<Page>

          4.1.2 JOINT OWNERSHIP. MBX and ADM Sub shall jointly own all Joint
Program Technology. ADM Sub hereby grants to MBX a perpetual, *, exclusive,
fully-sublicenseable license to ADM Sub's rights in Joint Program Technology for
the research, development, manufacture, use, sale and importation of PHA Related
Material produced via Plants. MBX hereby grants to ADM Sub a perpetual, *,
exclusive, fully-sublicenseable license to MBX's rights in Joint Program
Technology for use in all fields that are part of ADM's and its Affiliates'
commercial activities at any time during the tern of this Technology Alliance
Agreement, but excluding: (i) uses that are within the Field, (ii) uses that are
within the term "Field of Use" as that term is defined in the License Agreement
by and between MBX and Tepha, Inc. dated October 1, 1999 and (iii) any and all
uses of PHA Related Material produced via Plants. Subject to the rights,
licenses and obligations set forth herein, MBX and ADM Sub hereby agree that
they shall each have the right to assign, sell, license or otherwise convey
their rights in the Joint Program Technology without notice to or consent of the
other Party and without any obligation to share the proceeds of such activity
with the other Party, or otherwise to account to the other Party in connection
with such activities. In all other respects, the rights of the Parties as joint
owners shall be determined by the laws of the United States of America and the
State of Delaware.

          4.1.3 DISCLOSURE. MBX and ADM Sub shall each promptly disclose to the
other, in writing, the making, conception or reduction to practice of any
Program Technology.

     4.2 LICENSE GRANTS.

          4.2.1 LICENSE GRANTS BY MBX. Subject to the terms and conditions act
forth herein, MBX hereby grants to ADM Sub a *, non-exclusive license, without
the right to assign or sublicense, under MBX's right, title and interest in and
to the MBX Technology and the MBX Patent Rights, solely to perform its
obligations under the Technology Alliance Plan during the term of this
Agreement. ADM Sub acknowledges that certain of the MBX Patent Rights and MSX
Technology are Controlled by MBX pursuant and subject to that certain License
Agreement dated July 15, 1993 by and between MBX and Massachusetts Institute of
Technology as amended, the MIT License"). The license granted herein to ADM Sub
is subject to certain rights retained by MIT in the MIT License and ADM Sub
further agrees that the obligations to MIT set forth in Articles 2, 5, 7, 8, 9,
10, 12, 13 and 15 (copies of said articles am attached hereto as Exhibit H) are
binding upon ADM Sub as if it were a Party to the MIT License.

          4.2.2 GRANTS BY ADM SUB. Subject to the terms and conditions set forth
herein, ADM Sub hereby grants to MBX a *, non-exclusive license, without the
right to assign or sublicense, under ADM Sub's right, title and interest in and
to the ADM Sub Technology and the ADM Sub Patent Rights, solely to perform its
obligations under the Technology Alliance Plan during the term of this
Agreement.

     4.3 GRANT OF OPTION. MBX hereby grants to ADM Sub the might and option to
enter into a commercial alliance for the further research, development,
manufacture, use, sale and importation of the PHA Material and PHA Formulations
on the terms and conditions set forth in the Commercial Alliance Agreements (the
"Option"). The Option shall be exercisable by ADM Sub as follows: (i) at any
time after the Technical Aspects of the Goal have been achieved and until thirty
(30) days after the expiration of the term of this Agreement, by written notice
to

*    CONFIDENTIAL TREATMENT REQUESTED

                                       13

<Page>

MBX or (ii) at any time after the Fermentation Performance Parameters applicable
to fermentation in a * fermenter have been met and until thirty (30) days after
the expiration of the term of this Agreement, by written notice to MBX;
provided, however, that, in either case, the Option shall not be exercisable if
and for so long as ADM Sub is in breach of this Agreement. Following the
exercise of the Option, the Parties shall promptly execute and deliver the
Commercial Alliance Agreements in accordance with this Agreement.

     4.4 NO IMPLIED RIGHTS. The Parties hereby agree and acknowledge that no
rights or licenses under their respective intellectual property rights are
granted hereunder, by implication, estoppel or otherwise, by either of them,
except as expressly set forth in Section 4.1, Section 4.2 and Section 4.3.

     4.5 REPRESENTATIONS AND WARRANTIES.

          4.5.1 MBX REPRESENTATIONS. Except as otherwise disclosed on Schedule
4.5.1 attached hereto and incorporated herein by reference, MBX represents and
warrants, as of the Effective Date, that: (a) MBX possesses the full legal
right; authority and power to enter into this Agreement and to grant the license
to ADM Sub as set forth herein, and that no consent or approval is required in
connection therewith; (b) to MBX's Knowledge, the MBX Patent Rights are valid
and enforceable within the Field, and MBX has no Knowledge of any current or
threatened claim by a third party that any of the MBX Patent Rights are invalid
or unenforceable within the Field or that practicing any of the MBX Patent
Rights or MBX Technology within the Field would infringe a third party's Patent
Rights; (c) there is no existing or, to MBX's Knowledge, threatened litigation
concerning the ownership or use within the Field of the MBX Technology or MBX
Patent Rights; (d) all MBX Patent Rights that have been prosecuted by MBX
(directly or through legal counsel) have been prosecuted in good faith; (e) to
the Knowledge of MBX, all MBX Patent Rights that have been prosecuted by a third
party (directly or through legal counsel) have been prosecuted in good faith;
(f) MBX has not sold, transferred, granted any licenses, or otherwise conveyed
any rights in or to the MBX Technology or MBX Patent Rights that would prevent
MBX from granting the rights and licenses granted herein; (g) MBX shall not
Knowingly provide any false or misleading information to ADM Sub in connection
with the Technology Transfer or the performance of the Technical Alliance
Program; (h) MBX has disclosed to ADM Sub any information, which, to MBX's
Knowledge, identifies significant health or safety risks associated with the
production or recovery of PHA Material or PHA Formulations; (i) to its
Knowledge, MBX can fulfill its obligations hereunder without violating,
infringing or misappropriating any rights, including any contract, statutory or
intellectual property rights or any confidentiality rights of any third party;
(j) MBX has no Knowledge of any existing or threatened acts by any third party
that would infringe the MBX Technology or the MBX Patent Rights; (k) MBX has no
Knowledge of any prior art that would render the MBX Patent Rights unpatentable;
(l) the MBX Patent Rights include all of the patents and patent applications
which MBX Controls which would be infringed by the research, development,
manufacture, use, sale or importation of PHA Material and PHA Formulations;
provided, that if any such patents or patent applications are not encompassed
within the definition of the term "MBX Patent Rights", such definition shall be
construed as if such patents or patent applications were so included; (m) MBX
has provided ADM Sub with true copies of the agreements listed on Schedule 4.5.1
and that these agreements are all the agreements that are currently effective,
or entered into but effective after the Effective Date, that MBX or its

*    CONFIDENTIAL TREATMENT REQUESTED

                                       14

<Page>

Affiliates has entered into with third parties pursuant to which: (1) MBX or its
Affiliates has granted to a third party the right to practice the MBX Patent
Rights in the Field, (2) a Third Party granted to MBX or its Affiliates the
right to practice such third party's intellectual property rights within the
Field, (3) MBX or its Affiliates and a third party have or shall conduct
activities relating to the production or sale of PHA Material or PHA
Formulations, (4) MBX or its Affiliates shall have transferred or conveyed a
cell line intended to produce PHA Material to a third party, or (5) either party
shall manufacture, distribute or sell polyhydroxyalkanoates or concerning the
license of Technology or Patent Rights concerning the manufacture, distribution
or sale of polyhydroxyalkanoates, (n) Schedule 4.5.1 contains a complete list,
as of the Effective Date, of any written opinions of counsel MBX has received
concerning the patentability or enforceability of any MBX Patent Rights or
Patent Rights Controlled by any Third Party; (o) Schedule 4.5.1 contains a
complete list of all written notices MBX has received from any third parties
alleging that MBX is or maybe infringing a third party's patent or other
intellectual property right; and (p) Schedule 4.5.1 contains a complete list of
all written notices MBX has provided to any Third Party alleging that such Third
Party is or may be infringing MBX Technology or MBX Patent Rights. Anything
herein to the contrary notwithstanding, MBX shall only be required to provide
copies to ADM Sub of those material transfer agreements entered into with Third
Parties pursuant to which MBX or its Affiliates shall have transferred or
conveyed a cell line intended to produce PHA Material or that does not conform
in all material respects with the form of material transfer agreement attached
hereto to Schedule 4.5.1. Anything herein to the contrary notwithstanding, the
Parties hereby agree and acknowledge as follows: (i) with respect to such of the
Technology and Patent Rights that are Controlled by MBX and that include or
claim processes or methods ("Methods IP") of manufacturing, processing or using
compositions of matter, it is acknowledged that MBX may not have, or be able to
license to ADM Sub or the Joint Sales Company hereunder, the freedom to practice
such Methods IP with respect to compositions that are owned or controlled by
Third Parties and that MBX makes no representation or warranty as to such
freedom to operate; (ii) with respect to such of the Technology and Patent
Rights that are Controlled by MBX and that include or claim compositions of
matter of PHA Formulations ("Formulations IP"), it is acknowledged that MBX may
not have, or be able to license to AIM Sub or the Joint Sales Company hereunder,
the fight to make, use or sell PHA Formulations that are claimed by such
Formulations IP to the extent that a Third Party owns or controls the right to
manufacture, use or sell a component, ingredient or combination that is included
within a particular PHA Formulation and that MBX makes no representation or
warranty as to such freedom to operate; provided, however, that except to the
extent recently allowed US Patent Application US 2003/0236358 (published
December 25, 2003) is valid, enforceable and applicable, this exception shall
not apply to the formulations listed on Schedule 4.5.1 as "Core Formulations";
(iii) with respect to such of the Technology and Patent Rights that are
Controlled by MBX and that include or claim a method producing PHA Material
through the use of engineered microbial cell lines, MBX believes that *, (iv)
with respect to such of the Technology and Patent Rights that are Controlled by
MBX and that include or claim the manufacture, use or sale of *; and (v) with
respect to patent applications that are included within the MBX Patent Rights,
MBX only makes the representations and warranties set forth in items 4.5.1(a),
(c), (d), (e), (f), (g), (j), (k), (I), (m) and (n). MBX DOES NOT MAKE ANY OTHER
REPRESENTATION OR WARRANTY WHATSOEVER CONCERNING THE MBX PATENT RIGHTS, THE MBX
TECHNOLOGY OR ITS RIGHTS THEREIN. MBX HEREBY SPECIFICALLY DISCLAIMS ALL OTHER
WARRANTIES, EXPRESS OR

*    CONFIDENTIAL TREATMENT REQUESTED

                                       15

<Page>

IMPLIED, INCLUDING BUT NOT LIMITED TO, IMPLIED WARRANTIES OF MERCHANTABILITY AND
FITNESS FOR A PARTICULAR PURPOSE.

          4.5.2 ADM SUB REPRESENTATIONS. Except as otherwise disclosed on
Schedule 4.5.2 attached hereto and incorporated herein by reference, ADM Sub
represents and warrants, as of the Effective Date, that: (a) ADM Sub possesses
the full legal right, authority and power to enter into this Agreement and to
grant the license to MBX as set forth herein, and that no consent or approval is
required in connection therewith; (b) to ADM Sub's Knowledge, the ADM Sub Patent
Rights that, to ADM Sub's Knowledge, have specific application within the Field,
are valid and enforceable within the Field, and ADM Sub has no Knowledge of any
current or threatened claim by a third party that any of the ADM Sub Patent
Rights that, to ADM Sub's Knowledge, have specific application within the Field,
are invalid or unenforceable within the Field or would infringe a third party's
Patent Rights if practiced in the Field; (c) there is no existing or, to ADM
Sub's Knowledge, threatened litigation concerning the ownership or use within
the Field of the ADM Sub Technology or ADM Sub Patent Rights than to ADM Sub's
Knowledge, have specific application within the Field; (d) all ADM Sub Patent
Rights that have been prosecuted by ADM or its Affiliates (directly or through
legal counsel) have been prosecuted in good faith; (e) to the Knowledge of ADM
Sub, all ADM Sub Patent Rights that have been prosecuted by a third party
(directly or through legal counsel) have been prosecuted in good faith; (f)
neither ADM Sub nor any of its Affiliates have sold, transferred, granted any
licenses, or otherwise conveyed any rights in or to the ADM Sub Technology or
ADM Sub Patent Rights that, to ADM Sub's Knowledge, have specific application
within the Field, which sale, transfer, license or conveyance would prevent ADM
Sub from granting the rights and licenses granted herein; (g) ADM Sub shall not
Knowingly provide any false or misleading information to MBX in connection with
the Technology Transfer or the performance of the Technical Alliance Program;
(h) ADM Sub has disclosed to MBX any information, which, to ADM Sub's Knowledge,
identifies significant health or safety risks associated with the production or
recovery of PHA Material or PHA Formulations; (i) to its Knowledge, ADM Sub can
fulfill its obligations hereunder without violating, infringing or
misappropriating any rights, including any contract, statutory or intellectual
property rights or any confidentiality rights of any third party; (j) ADM Sub
has no Knowledge of any existing or threatened acts by any third party that
would infringe the ADM Sub Technology or the ADM Sub Patent Rights that, to ADM
Sub's Knowledge, have specific application within the Field; (k) ADM Sub has no
Knowledge of any prior art that would render unpatentable those ADM Sub Patent
Rights that, to ADM Sub's Knowledge, have specific application within the Field,
(l) the ADM Sub Patent Rights include all of the patents and patent applications
which ADM Sub Controls which would be infringed by the research, development,
manufacture, use, sale or importation of PHA Material and PHA Formulations;
provided, that if any such patents or patent applications are not encompassed
within the definition of the term "ADM Sub Patent Rights", such definition shall
be construed as if such patents or patent applications were so included, (m) ADM
Sub has provided MBX with true copies of the agreements listed on Schedule 4.5.2
and that these agreements are all the agreements that are currently effective,
or entered into bat effective after the Effective Date, that ADM Sub or its
Affiliates has entered into with third parties pursuant to which: (1) ADM Sub or
its Affiliates has granted to a third party the right to practice within the
Field the ADM Sub Patent Rights that, to ADM Sub's Knowledge have specific
application within the Field, (2) a Third Party granted to ADM Sub or its
Affiliates the right to practice such third party's intellectual property rights
specifically within the Field, (3) ADM Sub or its

*    CONFIDENTIAL TREATMENT REQUESTED

                                       16

<Page>

Affiliates and a third party have or shall conduct activities relating to the
production or sale of PHA Material or PHA Formulations, (4) ADM Sub or its
Affiliates shall have transferred or conveyed a cell line intended to produce
PHA Material to a third party, or (5) either party shall manufacture, distribute
or sell polyhydroxyalkanoates or concerning the license of Technology or Patent
Rights concerning the manufacture, distribution or sale of
polyhydroxyalkanoates, (n) Schedule 4.5.2 contains a complete list, as of the
Effective Date, of any written opinions of counsel ADM Sub or its Affiliates
have received concerning the patentability or enforceability of any ADM Sub
Patent Rights or Patent Rights Controlled by any Third Party that, to ADM Sub's
Knowledge, have specific application within the Field; (o) Schedule 4.5.2
contains a complete list of all written notices ADM Sub has received from any
third parties alleging that ADM Sub or its Affiliates is or may be infringing a
third party's patent or other intellectual property right within the Field; and
(p) Schedule 4.5.2 contains a complete list of all written notices ADM Sub or
its Affiliates has provided to any Third Party alleging that such Third Party is
or may be infringing ADM Sub Technology or ADAM Sub Patent Rights within the
Field. Anything herein to the contrary notwithstanding, ADM Sub shall only be
required to provide copies to MBX of those material transfer agreements entered
into with Third Parties pursuant to which ADM Sub or its Affiliates shall have
transfer red or conveyed a cell line intended to produce PHA Material or that do
not provide that ADM Sub will own, or have an option to take an exclusive
license to inventions that relate to the manufacture, use or sale of PHA
Material that are made in connection with the work done pursuant to the material
transfer agreement. Anything herein to the contrary notwithstanding, the Parties
hereby agree and acknowledge as follows: with respect to patent applications
that are included within the ADM Sub Patent Rights, ADM only makes the
representations and warranties set forth in items 4.5.2(a), (c), (d), (e), (f),
(g), (j), (k), (1), (m) and (n). ADM SUB DOES NOT MAKE ANY OTHER REPRESENTATION
OR WARRANTY WHATSOEVER CONCERNING THE ADM SUB PATENT RIGHTS, THE ADM SUB
TECHNOLOGY OR ITS RIGHTS THEREIN. ADM SUB HEREBY SPECIFICALLY DISCLAIMS ALL
OTHER WARRANTIES, EXPRESS OR BELIED, INCLUDING BUT NOT LIMITED TO, IMPLIED
WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.

                                    ARTICLE 5
                                    PAYMENTS

     5.1 PAYMENTS. Within ten (10) days after the Effective Date, ADM Sub shall
pay to MBX the amount of three million dollars ($3,000,000) as a non-refundable;
non-creditable upfront payment. Within ten (10) days following the TAC's
determination that (i) the production of PHA Cell Paste in a fermenter having a
capacity of approximately * was in a manner and with results that met the
applicable Fermentation Performance Parameters, and (ii) the recovery of PHA
Material was in a manner and with results that met the Recovery Performance
Parameters, ADM Sub shall pay to MBX the amount of one million dollars
($1,000,000) as a non refundable, non-creditable milestone payment. Within ten
(10) days following the first to occur of: (i) the achievement of the Goal and
(ii) the exercise of the Option by ADM Sub, ADM Sub shall pay to MBX the amount
of one million dollars ($1,000,000) as a non refundable, non-creditable
milestone payment. Anything herein to the contrary notwithstanding, in the event
that ADM Sub desires to exercise the Option in accordance with Section 4.3, the
above-described upfront payment and the two (2) milestone payments, to the

*    CONFIDENTIAL TREATMENT REQUESTED

                                       17

<Page>

extent not already paid, shall be due and payable in full as a pre-condition to
the exercise of the Option. Amounts due under this Section 5.1 shall be payable
by wire transfer of immediately available funds to an MBX bank account in
accordance with instructions to be provided to ADM Sub by MBX.

     5.2 OTHER EXPENSES. Except as provided in Section 5.1, each Party shall
bear its own costs and expenses incurred in performing under this Agreement.

                                    ARTICLE 6
                                   EXCLUSIVITY

     6.1 EXCLUSIVITY. During the term of this Agreement, and for a period of
thirty (30) days thereafter, ADM Sub and MBX shall not, directly or through one
or more Affiliates or agents, discuss, negotiate or establish, business
operations, agreements or transactions with any third party concerning or
relating to *, including without limitation any business operation, agreement or
transaction that would have as a purpose, the manufacture, use, sale or
importation of *. Notwithstanding the foregoing, MBX shall at all times be
permitted to engage in the following activities: (i) communicate with and supply
PHA Material and PHA Formulations to potential and actual customers or marketing
partners from the PHA Material to be produced by ADM Sub and MBX hereunder, (ii)
establish fermentation, recovery and formulation capacity, directly or through
third party service providers, to produce, sell and convey pilot scale
quantities of PHA Material for market development purposes, to supply MBX
customers or to satisfy certain obligations of MBX hereunder, (iii) discuss,
negotiate or establish strategic marketing alliances, (iv) in-license or
otherwise acquire rights to Technology that may be useful in connection with the
activities of the Parties hereunder, or under the Commercial Alliance
Agreements, provided that such Technology is made available for use in
connection with such activities (the activities listed in the foregoing clauses
(i) through (iv) inclusive are the "Permitted Activities") and provided further
that, for avoidance of doubt, MBX shall not grant any right or license to any
MBX Technology for use within the Field to any Person other than to carry out
any of the Permitted Activities. MBX shall provide written notice to ADM Sub
describing any Permitted Activities that it plans to undertake and shall provide
ADM Sub with a reasonable opportunity to provide continents thereon to MSX.
Promptly upon ADM Sub exercising the Option hereunder, MBX shall assign to the
Joint Sales Company (and the Joint Sales Company shall assume) any and all
agreements entered into within the Permitted Activities concerning the supply of
PHA Material and PHA Formulations, any strategic marketing alliances and any
licenses to MBX Technology. Any amounts received by MBX in connection with any
strategic marketing alliance or in connection with any license to MBX Technology
in the Field permitted within the Permitted Activities shall be used solely to
further develop the MBX Technology within the Field.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       18

<Page>

                                   ARTICLE 7
                     TREATMENT OF CONFIDENTIAL INFORMATION;
                           PUBLICITY; NON-SOLICITATION

     7.1 CONFIDENTIALITY OBLIGATIONS. MBX and ADM Sub each recognize that the
other Parties' Confidential Information and Proprietary Materials constitute
highly valuable and proprietary confidential information. Each of MBX and ADM
Sub agrees that it will keep confidential, and will cause its employees,
consultants, and Affiliates to keep confidential, all Confidential Information
and Proprietary Materials of the other Parties. The Party and their respective
employees, consultants or Affiliates, shall not use any Confidential Information
or Proprietary Materials of any other Party for any purpose whatsoever except as
expressly permitted in this Agreement. MBX acknowledges that the corn costs that
constitute a portion of the Manufacturing Cost shall constitute ADM Sub
Confidential Information.

     7.2 LIMITED DISCLOSURE. MBX and ADM Sub each agree that any disclosure of
any other Party's Confidential Information or any transfer of any other Party's
Proprietary Materials to any officer or employee of any other Party or any of
its Affiliates shall be made only if and to the extent necessary to carry out
its rights and responsibilities under this Agreement and shall be limited to the
maximum extent possible consistent with such rights and responsibilities. MBX
and ADM Sub each further agree that any disclosure of another Party's
Confidential Information or any transfer of another Party's Proprietary
Materials as permitted by the preceding sentence shall only be made to such of
the recipient Party's officers, employees aid Affiliates who are bound by
written confidentiality obligations to maintain the confidentiality thereof and
not to use such Confidential Information or Proprietary Materials except as
expressly permitted by this Agreement. MBX and ADM Sub each further agree not to
disclose or transfer any other Party's Confidential information or Proprietary
Materials to any third parties under any circumstance without the prior written
approval from the relevant other Party (such approval not to be unreasonably
withheld), except as otherwise required by law, or except as otherwise expressly
permitted by this Agreement. Each Party shall take such action, and shall cause
its Affiliates to take such action, to preserve the confidentiality of the other
Parties' Confidential Information and Proprietary Materials as it would
customarily take to preserve the confidentiality of its own Confidential
Information and Proprietary Materials, and in no event, less than reasonable
care. Each Party, upon the request of any other Party, will return all the
Proprietary Information and Confidential Materials disclosed or transferred to
it by such other Party pursuant to this Agreement which does not constitute
Joint Program Technology, including all copies and extracts of documents and all
manifestations in whatever form, within two (2) months of the request or, within
two (2) weeks of the termination or expiration of this Agreement; provided,
however, that a Party may retain Confidential Information, and Proprietary
Materials of another Party relating to any license which survives such
termination and one copy of all other Confidential Information may be retained
in its legal files solely for the purpose of monitoring compliance with this
Article 7.

     7.3 EMPLOYEES AND CONSULTANTS. MBX and ADM Sub each hereby represent that
all of its employees, and any consultants to such Party or its Affiliates,
participating in the activities of the Technology Alliance Program who shall
have access to the Confidential Information or Proprietary Materials of the
other Party are bound by written obligations to maintain such information in
confidence and not to use such information except as expressly permitted herein

*    CONFIDENTIAL TREATMENT REQUESTED

                                       19

<Page>

mid to assign any inventions or discoveries made in connection with such
activities to MBX or ADM Sub as applicable. Each Party agrees to be held
responsible for the confidentiality obligations to which its employees and
consultants (and those of its Affiliates) are obligated.

     7.4 PUBLICITY. Neither Party may publicly disclose the existence or terms
of this Agreement without the prior written consent of the other Party;
provided, however, that either Party may make such a disclosure: (a) to the
extent required by law (including the fling of a redacted copy of the Agreement
as an exhibit to a legally required filing) or by the requirements of any
nationally recognized securities exchange, quotation system or over-the-counter
market on which such Party has its securities listed or traded, and (b) to any
investors (including without limitation, entities interested in acquiring the
stock or assets of such Party or merging with or into such Party), prospective
investors, lenders, other potential financing sources, prospective customers and
prospective strategic marketing partners who are obligated to keep such
information confidential. In the event that such disclosure is required as
aforesaid, the disclosing Party shall make Commercially Reasonable Efforts to
provide the other Party with reasonable notice prior to such disclosure and to
coordinate with the other Party with respect to the wording and timing of any
such disclosure. The Parties, prior to the execution of this Agreement, will
mutually agree on the wording of a press release publicizing the Technology
Alliance which shall be attached hereto as Exhibit I. Once such press release or
any other written statement is approved for disclosure by both Parties, either
Party may make subsequent public disclosure of the contents of such statement,
but no more than the contents of such statement, without the further approval of
the other Party.

     7.5 PROHIBITION ON SOLICITATION. Neither Party nor its Affiliates shall,
during the period commencing on the Effective Date and continuing until the
expiration or termination of this Agreement and two (2) years thereafter,
specifically solicit any person who is employed by the other Party or its
Affiliates and who was involved in the Technology Alliance Program during the
term of this Agreement, whether such person is solicited to be hired as an
employee or consultant, unless authorized in writing by the other Party. The
Parties acknowledge that generally listing a position for hire in a newspaper,
trade journal or similar publication shall not constitute a specific
solicitation in violation of the terms of this provision. The Parties also
acknowledge that specifically soliciting any person who was formerly employed by
the other Party or its Affiliates is not in violation of the terms of this
provision. The Parties further acknowledge for the avoidance of doubt that this
Section only applies to those persons that remain employees of a Party and not
to former employees of a Party.

     7.6 TERM. The obligations and restrictions set forth in this Article 7
shall survive the termination or expiration of this Agreement for a period of
twenty (20) years.

                                   ARTICLE 8
                              TERM AND TERMINATION

     8.1 TERM. This Agreement shall commence as of the Effective Date and shall
expire upon the first to occur of (i) fifteen (15) months following the
completion of the initial fermentation run by ADM Sub in a fermenter having a
capacity of approximately *, (ii) eighteen (18) months following the completion
of MBX's obligations in connection with the Technology

*    CONFIDENTIAL TREATMENT REQUESTED

                                       20

<Page>

Transfer as specified under the Technology Alliance Plan, (iii) the second
anniversary of the Effective Date, unless terminated in accordance with this
Article 8 prior to such date, and (iv) the execution of the Commercial Alliance
Agreement.

     8.2 TERMINATION BY EITHER PARTY. This Agreement may be terminated at any
time by either Party in the event that the other Party materially defaults on
any material obligation hereunder or materially breaches any material term of
this Agreement to be performed or observed: (a) by giving one (1) month prior
written notice to the defaulting Party in the case of a breach of any payment
term of this Agreement, and (b) by giving two (2) months prior written notice to
the defaulting Party in the case of any other breach; provided, however, that in
the case of a default or breach capable of being cured, if said defaulting Party
shall cure the said default or breach within such notice period after said
notice shall have been given, then said notice shall not be effective and this
Agreement shall continue in full force and effect.

     8.3 AT WILL TERMINATION BY ADM SUB. ADM Sub shall have the right to
terminate this Agreement at any time upon not less than one (1) month prior
written notice to MBX.

     8.4 CONSEQUENCES OF TERMINATION OR EXPIRATION; GRANT OF LICENSES. Upon the
termination or expiration of the Agreement, the following shall occur:

          8.4.1 CONSEQUENCES OF TERMINATION OR EXPIRATION.

               (a)  MBX shall immediately cease using, and shall promptly return
                    to ADM Sub, all ADM Sub Technology, except to the extent MBX
                    has a license to practice such Technology under Section 8.4;

               (b)  ADM Sub shall immediately cease using, and shall promptly
                    return to MBX all MBX Technology, except to the extent ADM
                    Sub has a license to practice such Technology under Section
                    8.4;

               (c)  the license granted to ADM Sub pursuant to Section 4.2.1
                    shall immediately terminate;

               (d)  the license granted to MBX pursuant to Section 4.2.2 shall
                    immediately terminate;

               (e)  each Party shall promptly pay to the other any amounts due
                    and payable hereunder as of the effective date of
                    termination or expiration; and

               (f)  subject to those rights and obligations of the Parties that
                    survive termination or expiration by their terms or pursuant
                    to Section 8.5, this Agreement shall terminate and be of no
                    further force or effect.

          8.4.2 RIGHTS UPON ADM SUB TERMINATION.

               (a)  In the event ADM Sub terminates this Agreement pursuant to
                    Section 8.3, or ADM Sub does not Exercise the Option after
                    the

*    CONFIDENTIAL TREATMENT REQUESTED

                                       21

<Page>

                    Technical Aspects of the Goal have been achieved, then ADM
                    Sub shall and hereby does grant to MINX a
                    fully-sublicenseable, *, perpetual, irrevocable,
                    non-exclusive license under all intellectual property rights
                    Controlled by ADM Sub and claiming or covering Program
                    Technology, to research, develop, manufacture, use, sell and
                    import PHA-Related Material, produced using any means or
                    methods, for any rand all uses.

               (b)  In the event ADM Sub terminates this Agreement pursuant to
                    Section 8.2, then MBX shall and hereby does grant to ADM Sub
                    a fully-sublicenseable, *, perpetual, irrevocable (unless
                    the terms of the license are breached), non-exclusive
                    license under all intellectual property rights Controlled by
                    MBX and claiming or covering Program Technology and MBX
                    Background Technology to research, develop, manufacture,
                    use, sell and import PHA Material and PHA Formulations for
                    use in the Field. The foregoing license shall be limited
                    such that ADM Sub shall be permitted to make a maximum of *
                    of PHA Materials during each consecutive period of twelve
                    (12) months during the term of the license on a * basis and
                    ADM Sub shall have the right to make up to an additional *
                    of PHA Material during each consecutive period of twelve
                    (12) months during the term of the license subject to
                    payment to MBX of a royalty (i) during the Royalty Term
                    equal to: (y) * on all sales or other conveyances of PHA
                    Patented Material (including, without limitation, PHA
                    Material that is contained within PHA Formulations), on a
                    one hundred percent (100%) purity basis; and (z) * on all
                    sales or other conveyances of PHA Know How Material
                    (including, without limitation, PHA Material that is
                    contained within PHA Formulations), on a one hundred percent
                    (100%) purity basis; and (ii) during the Supplemental
                    Royalty Term equal to * on all sales or other conveyances of
                    PHA Supplemental Know How Material (including, without
                    limitation, PHA Material that is contained within PHA
                    Formulations), on a one hundred percent (100%) purity basis.
                    Provided, however, that any such royalty shall be reduced by
                    the amount of royalties payable to any Third Party under a
                    license required to obtain freedom to practice the MBX
                    Technology and/or MBX Patent Rights for the manufacture, use
                    or sale of PHA Material within the Field provided that MBX
                    breached an obligation under Section 4.5.1 to disclose: (i)
                    the existence of such Third Party's intellectual property
                    rights in such Technology, or (ii) claims by such Third
                    Party that any of the MBX Patent Rights are invalid or
                    unenforceable, or that the practice of any of the MBX Patent
                    Rights would constitute an infringement or misappropriation
                    of such Third Party's intellectual property rights (such
                    royalty reduction right is "Third Party IP Royalty Offset").
                    Such royalty shall be payable within thirty (30) days
                    following the end of each

*    CONFIDENTIAL TREATMENT REQUESTED

                                       22

<Page>

                    calendar quarter for sales or conveyances that occur during
                    such calendar quarter. Amounts due under this Section
                    8.4.2(b) shall be payable by wire transfer of immediately
                    available funds to an MBX bank account in accordance with
                    instructions to be provided to ADM Sub by MBX. Any amounts
                    that are not paid when due hereunder shall accrue interest
                    at the rate of four percent (4%) per annum in excess of the
                    one year London Interbank Offered Rate (LIBOR) then most
                    recently published in THE WALL STREET JOURNAL. The right to
                    demand and receive the interest provided hereunder shall be
                    in addition to any other rights available to MBX hereunder
                    or at law. ADM Sub shall maintain records with respect to
                    the sale or conveyance of PHA Material under this license in
                    sufficient detail to enable MBX to verify the accuracy of
                    the royalty payments made hereunder by ADM Sub. Such records
                    shall be retained for at least five (5) years after the
                    relevant (late of sale or conveyance. MBX shall have the
                    right, during normal business hours and upon reasonable
                    notice, to have an independent third party accounting firm
                    (subject to a mutually agreeable confidentiality agreement)
                    inspect and copy any such records that are maintained in
                    accordance with this Section 8.4.2(b). ADM Sub may terminate
                    this license at any time without any further obligation by
                    providing MBX with written notice thereof. In addition, in
                    the event ADM Sub terminates this Agreement pursuant to
                    Section 8.2, MBX shall promptly destroy any derivatives and
                    mutated forms constituting MBX Proprietary Materials
                    invented by ADM Sub, and provide ADM Sub with a
                    certification signed by an officer of MBX that MBX has
                    complied with this provision.

          8.4.3 RIGHTS UPON MBX TERMINATION. In the event MBX terminates this
Agreement pursuant to Section 8.2, then ADM Sub shall and hereby does grant to
MBX: (i) a fully-sublicenseable, *, perpetual, irrevocable, exclusive license
under all intellectual property rights Controlled by ADM Sub and claiming or
covering Program Technology, to research, develop, manufacture, use, sell and
import PHA Related Material, produced using any means or methods, for any and
all uses, and (ii) a fully-sublicenseable, *, perpetual, irrevocable,
non-exclusive license under all ADM Sub Background Technology, to research,
develop, manufacture, use, sell and import PHA-Related Material, produced using
any means or methods, for any and all uses.

          8.4.4 RIGHTS UPON BANKRUPTCY.

               (a)  In the event ADM Sub files for protection under Chapter 11
                    of the U.S. Bankruptcy Code, and ADM Sub, directly or
                    indirectly in connection with such proceedings, rejects this
                    Agreement as an executory contract (or on similar grounds),
                    then ADM Sub shall and hereby does grant to MBX: (i) a
                    fully-sublicenseable, *, perpetual, irrevocable, exclusive
                    license under all intellectual

*    CONFIDENTIAL TREATMENT REQUESTED

                                       23

<Page>

                    property rights Controlled by ADM Sub and claiming or
                    covering Program Technology, to research, develop,
                    manufacture, use, sell and import PHA-Related Material,
                    produced using any means or methods, for any and all uses,
                    and (ii) a fully-sublicenseable, *, perpetual, irrevocable,
                    non exclusive license under all ADM Sub Background
                    Technology, to research, develop, manufacture, use, sell and
                    import PHA-Related Material, produced using any means or
                    methods, for any and all uses.

               (b)  In the event MBX files for protection under Chapter 11 of
                    the U.S. Bankruptcy Code, and MBX, directly or indirectly in
                    connection with such proceedings, rejects this Agreement as
                    an executory contract (or on similar grounds), then MBX
                    shall and hereby does grant to ADM Sub a
                    fully-sublicenseable, *, perpetual, irrevocable (unless the
                    terms of the license are breached), nonexclusive license
                    under all intellectual property rights Controlled by MBX and
                    claiming or covering Program Technology and MBX Background
                    Technology to research, develop, manufacture, use, sell and
                    import PHA Material and PHA Formulations for use in the
                    Field. The foregoing license shall be limited such that ADM
                    Sub shall be permitted to make a maximum of * of PHA
                    Materials during each consecutive period of twelve (12)
                    months during the term of the license on a * basis and ADM
                    Sub shall have the right to make up to an additional * of
                    PHA Material during each consecutive period of twelve (12)
                    months during the term of the license subject to payment to
                    MBX of a royalty (i) during the Royalty Term equal to: (y) *
                    on all sales or other conveyances of PHA Patented Material
                    (including, without limitation, PHA Material that is
                    contained within PHA Formulations), on a one hundred percent
                    (1.00%) purity basis; and (z) * on all sale or other
                    conveyances of PDA Know-How Material (including, without
                    limitation, PHA Material that is contained within PHA
                    Formulations), on a one hundred percent (100%) purity basis;
                    and (ii) during the Supplemental Royalty Term equal to * on
                    all sales or other conveyances of PHA Supplemental Know-How
                    Material (including, without limitation, PHA Material that
                    is contained within PHA Formulations), on a one hundred
                    percent (100%) purity basis. Provided, however, that any
                    such royalty shall be subject to Third Party IP Royalty
                    Offset. Such royalty shall be payable within thirty (30)
                    days following the end of each calendar quarter for sales or
                    conveyances that occur during such calendar quarter. Amounts
                    due under this Section 8.4.4(b) shall be payable by wire
                    transfer of immediately available funds to an MBX bank
                    account in accordance with instructions to be provided to
                    ADM Sub by MBX. Any amounts that are not paid when due
                    hereunder shall accrue interest at the rate of four percent
                    (4%) per annum in excess of the one year London Interbank
                    Offered Rate (LIBOR) then most recently

*    CONFIDENTIAL TREATMENT REQUESTED

                                       24

<Page>

                    published in THE WALL STREET JOURNAL. The right to demand
                    and receive the interest provided hereunder shall be in
                    addition to any other rights available to MBX hereunder or
                    at law. ADM Sub shall maintain records with respect to the
                    sale or conveyance of PHA Material under this license in
                    sufficient detail to enable MBX to verify the accuracy of
                    the royalty payments made hereunder by ADM Sub. Such records
                    shall be retained for at least five (5) years after the
                    relevant date of sale or conveyance. MBX shall have the
                    right, during normal business hours and upon reasonable
                    notice, to have an independent third party accounting firm
                    (subject to a mutually agreeable confidentiality agreement)
                    inspect and copy any such records that are maintained in
                    accordance with this Section 8.4.4(b). ADM Sub may terminate
                    this license at any time without any further obligation by
                    providing MBX with written notice thereof.

     8.5 SURVIVING PROVISIONS; RESERVATION OF RIGHTS. Termination or expiration
of this Agreement for any reason shall be without prejudice to any rights and
obligations of the Parties that have accrued as of the Effective Date of
termination and:

          (a) the rights and obligations of the Parties provided hi Section 8.4,
and Articles 1, 4, 6, 7, 9, 10 and 11 and any other provision which would
reasonably be expected to survive termination in accordance with the terms of
this Agreement, all of which shall survive such termination for the period of
time set forth in each such provision, or indefinitely if no such time is
specified; and

          (b) any other rights or remedies provided at law or equity which
either Party may otherwise have against the other.

                                    ARTICLE 9
                                 PATENT MATTERS

     9.1 PATENT FILING, PROSECUTION AND MAINTENANCE.

          9.1.1 ADM SUB PATENT RIGHTS. ADM Sub shall have the sole right and
authority to file, prosecute and maintain the ADM Sub Patent Rights during the
term of this Agreement at its own expense and using patent counsel of its own
choosing. ADM Sub represents that it will continue to file, prosecute and
maintain the ADM-Sub Patent Rights in accordance with reasonable commercial
practices during the term of this Agreement.

          9.1.2 MBX PATENT RIGHTS. MBX shall have the sole right and authority
to file, prosecute and maintain the MBX Patent Rights during the term at its own
expense and using patent counsel of its own choosing. MBX represents that it
will continue to file, prosecute and maintain the MBX Patent Rights in
accordance with reasonable commercial practices during the term of this
Agreement.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       25

<Page>

          9.1.3 ABANDONMENT. If either Party decides to withdraw from the
continued prosecution of any Patent Rights on Technology that is at that time
subject to a license hereunder, such Party shall so inform the other Party at
least thirty (30) days prior to the effective date of such decision and the
other Party shall have the right, through patent attorneys or agents of its
choice, to assume responsibility for the continued prosecution of such Patent
Rights. Promptly after the effective date of the decision to withdraw, the
withdrawing Party shall assign its right, title and interest in and to such
Patent Rights to the other Party. Notwithstanding such assignment, such Patent
Rights will continue to be subject to any licenses granted herein to the extent
necessary in carrying out the Commercial Alliance.

          9.1.4 JOINT PROGRAM TECHNOLOGY. The Parties will file, prosecute and
maintain Patent Rights claiming Joint Program Technology in accordance with this
Section 9.1.4 with the primary goal of maximizing the commercial potential of
the PHA Material in a commercially reasonable manner. The Parties, sharing
expenses equally and acting through patent attorneys or agents agreed upon by
the Parties, shall prepare, file, prosecute and maintain all Patent Rights
relating to Joint Program Technology. If either Party decides to withdraw from
the continued prosecution of any Patent Rights on Joint Program Technology, such
Party shall so inform the other Party at least thirty (30) days prior to the
effective date of such decision and the other Party shall have the right,
through patent attorneys or agents of its choice, to assume responsibility for
the continued prosecution of such Patent Rights. Promptly after the effective
date of the decision to withdraw, the withdrawing Party shall assign its right,
title and interest in and to such Patent Rights to the other Party.
Notwithstanding such assignment, such Patent Rights will continue to be subject
to the licenses granted herein to the extent applicable.

     9.2 INFRINGEMENT AND DEFENSE.

          9.2.1 ACTUAL OR THREATENED INFRINGEMENT. In the event either Party
becomes aware of any possible infringement or unauthorized possession, knowledge
or use of any Technology, which is the subject matter of this Agreement, in the
Field (collectively, an "Infringement"), that Party shall promptly notify the
other Party and provide it with available details. ADM Sub hereby reserves the
exclusive right (but not obligation) to take whatever action it deems
appropriate to prevent or terminate any third party infringement of ADM Sub
Patent Rights claiming the ADM Sub Technology, at ADM Sub's cost. MBX hereby
reserves the exclusive right (but not obligation) to take whatever action it
deems appropriate to prevent or terminate any third party infringement of MBX
Patent Rights claiming the MBX Technology, at MBX's cost. Notwithstanding the
foregoing, during the term, if either Party (the "Defending Party") decides to
take any action to prevent or terminate any third party infringement of its
Patent Rights within the Field, it shall first give notice to the other Party
(the "Neutral Party") and, if the Neutral Party can produce a written legal
opinion of an independent patent attorney concluding that there is a reasonable
likelihood that such third party could, in good faith, in connection with such
action, allege that a claim or claims within Patent Rights Controlled by the
Neutral Party are invalid or unenforceable, then the Defending Party shall not
take such action against such third party without the prior, written consent of
the Neutral Party. The Parties, sharing expenses equally and acting through
patent attorneys or agents agreed upon by the Parties, shall take whatever
action they shall agree upon to prevent or terminate any third party
infringement of Patent Rights relating to Joint Program Technology, provided,
however, that if the Parties cannot agree, MBX shall have the right to make the
final determination with respect

*    CONFIDENTIAL TREATMENT REQUESTED

                                       26

<Page>

to third party infringement within the Field. In all cases, all decisions by a
Party pursuant to this Section 9.2 shall be made in good faith and in the best
interest of the Technology Alliance Program.

          9.2.2 DEFENSE OF CLAIMS. In the event that any action, suit or
proceeding is brought against either Party based on its actions in performance
of the Technology Alliance Program and alleging the infringement of the
Technology or intellectual property rights of a third party, the Parties shall
cooperate with each other in the defense of any such suit, action or proceeding.
The Parties will give each other prompt written notice of the commencement of
any such suit, action or proceeding or claim of infringement and will furnish
each other with a copy of each communication relating to the alleged
infringement. Each Party shall cooperate in the defense of such actions. If as a
consequence of such action, suit or proceeding by a third party, a prohibition,
restriction or other condition is imposed upon one or both of the Parties, the
Parties shall examine and discuss in good faith the consequences of such
prohibition or restriction or other conditions on this Agreement and on possible
modifications hereto.

                                   ARTICLE 10
                                 INDEMNIFICATION

     10.1 INDEMNIFICATION BY MBX. During the course of, and upon and after
termination of this Agreement for any reason whatsoever, MBX and its Affiliates
shall indemnify, defend and hold ADM Sub, its Affiliates and their respective
directors, officers and employees (collectively, "ADM Sub Indemnitees") harmless
against any claims (including without limitation claims for product liability,
personal injury or death, or property damage), liability, damage, loss, cost or
expense (including reasonable attorneys' fees) incurred by any of them, to the
extent resulting from: (i) the * of MBX, or any of its Affiliates, or their
respective employees, representatives or agents; or (ii) MBX's *.
Notwithstanding anything to the contrary, this provision shall not apply to any
claims or suits to the extent attributable to the negligence or willful
misconduct of air ADM Sub Indemnitee or a breach of this Agreement by ADM Sub.

     10.2 INDEMNIFICATION BY ADM SUB. During the course of, and upon and after
termination of this Agreement for any reason whatsoever, ADM Sub and its
Affiliates shall indemnify, defend and hold MBX, its Affiliates and their
respective directors, officers and employees (collectively, "MBX Indemnitees")
harmless against any claims (including without limitation claims for product
liability, personal injury or death, or property damage), liability, damage,
loss, cost or expense (including reasonable attorneys' fees) incurred by any of
them, to the extent resulting from: (i) the * of ADM Sub, or any of its
Affiliates, or their respective employees, representatives or agents; or (ii)
ADM Sub's *. Notwithstanding anything to the contrary, this provision shall not
apply to any claims or suits to the extent attributable to the negligence or
willful misconduct of an MBX Indemnitee or a breach of this Agreement by MBX.

     10.3 CONDITIONS TO INDEMNIFICATION. A Party seeking indemnification under
this Article 10 (the "Indemnified Party') shall give prompt notice of the claim
to the other Party (the "Indemnifying Party) and, provided that the Indemnifying
Party is not contesting the indemnity obligation, shall permit the Indemnifying
Party to control any litigation relating to such claim and disposition of any
such claim, provided that the Indemnifying Party shall act reasonably and

*    CONFIDENTIAL TREATMENT REQUESTED

                                       27

<Page>

in good faith with respect to all matters relating to the settlement or
disposition of any claim as the settlement or disposition relates to Parties
being indemnified under this Article 10 and provided, further, that the
Indemnifying Party shall not settle or otherwise resolve any claim without prior
notice to the Indemnified Party and the consent of the Indemnified Party (which
consent shall not be unreasonably withheld, conditioned or delayed) if such
settlement involves anything other than the payment of money by the Indemnifying
Party. The Indemnified Party shall cooperate with the Indemnifying Party in its
defense of any claim for which indemnification is sought under this Article 10
and shall have the right to be present hi person or through counsel at all legal
proceedings giving rise to the right of indemnification.

                                   ARTICLE 11
                                  MISCELLANEOUS

     11.1 NO ASSIGNMENT. No Party shall sell, transfer or permit any transfer
of, in whole or in part, this Agreement without prior written consent of the
other Parties, which consent may be withheld for any reason. The merger or
acquisition of MBX by, with or into a third party shall not be deemed to effect
an assignment of this Agreement by MBX and this Agreement shall be binding upon
and inure to the benefit of such third party, or new entity, in the case of a
merger or similar transaction in which MBX does not continue as the same
corporate entity and shall continue to bind and inure to the benefit of MBX in
the case of an acquisition or similar transaction in which MBX survives as the
same corporate entity. ADM Sub shall not enter into any merger, acquisition or
similar transaction without the prior, written consent of MBX. Nothing herein
shall restrict ADM from entering into a merger or acquisition of ADM by, with or
into a third party and no such transaction shall he deemed to effect an
assignment of this Agreement by ADM Sub and this Agreement shall be binding upon
and inure to the benefit of such third party, or new entity, in the case of a
merger or similar transaction in which ADM does not continue as the same
corporate entity and shall continue to bind and inure to the benefit of ADM Sub
in the case of an acquisition or similar transaction in which ADM survives as a
the same corporate entity. Any purported assignment or transfer in violation of
this provision shall be null and void. In the event that, at anytime *, MBX
receives a bona fide offer from a third party to acquire all, or a majority, of
the outstanding shares of voting equity of MBX (such an acquisition is
hereinafter an "Acquisition Transaction"), MBX shall provide notice to ADM Sub
of the proposed Acquisition Transaction at least * from ADM Sub to enter into an
Acquisition Transaction with ADM Sub (such an agreement is a "No-Shop
Agreement"). Such notice will set forth the *. ADM Sub shall not, directly or
indirectly, contact such proposing party without MBX's prior written consent,
provided however, that if such proposing party contacts ADM Sub without direct
or indirect prompting or solicitation by ADM Sub, then nothing in this Section
11.1 shall restrict ADM Sub's ability to communicate with such proposing party.
In the event that the * period, or thereafter at anytime before MBX has entered
into a No-Shop Agreement *, MBX will provide notice to ADM Sub of the terms of
such modified bona fide offer, including the same level of detail and
information as is required to be included in the original notice, at least forty
eight (48) hours (which forty eight (48) hour period must include at least one
(1) full business day) prior to entering into a No-Shop Agreement. For avoidance
of doubt, provided that MBX has complied with the foregoing notice requirements,
MBX shall have no obligation to provide any additional notice to ADM Sub of
changes to the tens of an offer after MBX has entered into a No-Shop Agreement
with respect to such transaction.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       28

<Page>

Notwithstanding the foregoing, if MBX *, the foregoing notice requirements shall
not apply, and *.

     11.2 SUCCESSORS. In the event of a permitted assignment, this Agreement
shall be binding upon, and inure to the benefit of, all the Parties and their
respective successors and legal assigns.

     11.3 DISPUTE RESOLUTION. Any dispute or claim arising out of or relating to
this Agreement, or breach thereof shall be resolved in accordance with this
Section 11.3. During the course of resolving any such dispute, the Parties shall
continue to perform their obligations hereunder (including by making payment of
the undisputed portion of any payment obligation that is the subject of a
dispute hereunder or thereunder). Notwithstanding the foregoing, the obligation
of the Parties to continue to perform hereunder during the resolution of
disputes shall not require a Party to perform obligations (other than any
undisputed portion of any payment obligations) where such performance is
rendered impossible, or would otherwise not maintain or increase the likelihood
that the Parties will achieve the purpose and Goal of the Technology Alliance,
because of circumstances created by or directly related to the dispute itself.

          11.3.1 GOOD FAITH CONSULTATION. In the event of a dispute between the
Parties, the Parties shall attempt in good faith to settle such dispute through
mutual consultation. If, after such consultation, the dispute cannot be
resolved, the Parties shall wait for not less than sixty (60) days after the
dispute arises and at the end of such period meet for a second consultation. If
the dispute is not resolved after the second consultation, the matter shall be
referred to the Senior Vice President (Corn Processing and Food Specialties) of
ADM Sub and the Chief Executive Officer of MBX (together, the "Senior
Executives") for resolution in accordance with Section 11.3.2.

          11.3.2 SENIOR EXECUTIVES. The Senior Executives shall diligently
attempt to resolve the dispute, including, if they deem it necessary, meeting
directly in order to provide full consideration of the dispute. If the Senior
Executives are unable to resolve the dispute within sixty (60) additional days
after the second consultation then the dispute shall be referred to arbitration.

          11.3.3 ARBITRATION. Any arbitration to be conducted hereunder shall be
brought and conducted in accordance with the following provisions:

               (1)  The arbitration shall be held in Chicago, Illinois if
                    initiated by MBX and in Boston, Massachusetts if initiated
                    by ADM Sub.

               (2)  The arbitration shall be conducted by three (3) arbitrators
                    in accordance with the commercial arbitration rules of the
                    American Arbitration Association. Each Party, upon notice to
                    the other Party, shall appoint one arbitrator. The two
                    arbitrators appointed by the Parties shall appoint a third
                    arbitrator. The arbitrators shall be lawyers who will have
                    substantial patent law or patent litigation experience and
                    substantial commercial law or commercial litigation
                    experience. The arbitrators shall be instructed to follow

*    CONFIDENTIAL TREATMENT REQUESTED

                                       29

<Page>

                    federal precedents, laws and evidentiary rules that would be
                    applicable to litigation in the Federal Court of the
                    jurisdiction in which the arbitration is held, except for
                    those issues which involve patent issues, in which case the
                    arbitrators shall be instructed to follow federal
                    precedents, laws and evidentiary rules that would be
                    applicable to litigation in the Federal Circuit Court of
                    Appeals.

               (3)  The arbitration shall be conducted in English, and all
                    written submissions shall be in English.

               (4)  The Parties agree that the decision of the arbitrators shall
                    be final and binding on the Parties. The decision of the
                    arbitrators shall be carried out voluntarily and without
                    delay.

               (5)  The fees and expenses of the arbitrators shall be shared
                    equally by the Parties. Each Party will bear its own costs
                    and expenses, including without limitation, its own legal
                    fees and expert witness fees. Notwithstanding the foregoing,
                    the Parties agree to be bound by and obey any order of the
                    arbitrators relating to one Party being liable for any such
                    costs, including without limitation, the legal fees of the
                    other Party.

          11.3.4 EQUITABLE RELIEF. Nothing in this Agreement shall prevent or
limit a Party's right to file and prosecute an action to seek injunctive relief
to prevent or stay a breach of this Agreement or any action necessary to enforce
the award of the arbitrators.

     11.4 GOVERNING LAW. Except as specifically otherwise provided herein, this
Agreement shall be governed by and construed in accordance with the laws of the
State of Delaware.

     11.5 FORCE MAJEURE. In the event of the intervention of a force majeure,
which term shall include, without limitation, acts of God, strikes, labor
disturbances, lockouts, riots, epidemics, quarantines, wars or conditions of
war, actions, inactions or regulations of any government, fires, acts of
terrorists, insurrections, embargoes or trade restrictions, or any other reasons
beyond a Party's reasonable control, the Party affected by the force majeure
shall use Commercially Reasonable Efforts to comply with the Agreement. In the
case that such Commercially Reasonable Efforts fail or are futile, such Party
shall not be responsible for delays or a failure to perform under this Agreement
caused by a force majeure. Provided, however, that any payment obligations of a
Party shall not be affected or excused by such force majeure. If a Party's delay
or failure to perform continues for more than one hundred twenty (120) days, the
other Party may terminate this Agreement. In the event that either Party shall
incur a delay in delivery or performance for a reason permitted by this Article,
that Party shall notify the other Party within five (5) days from the date of
the actual occurrence of the cause for such delay.

     11.6 NOTICES. All notices, requests and other communication hereunder shall
be in writing and sent by facsimile with confirmation sent by courier requiring
acknowledgment of receipt by the respective Parties as follows:

*    CONFIDENTIAL TREATMENT REQUESTED

                                       30

<Page>

          To MBX:         Metabolix Corporation
                          21 Erie Street
                          Cambridge, MA 02139-4260
                          Attn: President and CEO

          With copy to:   Mintz Levin Cohn Ferris Glovsky and Popeo PC
                          One Financial Center
                          Boston, MA 02111
                          Attn: Christopher J. Denn, Esq.

          To ADM Sub:     ADM Polymer Corporation
                          4666 Faries Parkway
                          Decatur, IL 62526
                          Attn: President

          With copy to:   Asher-Daniels-Midland Company
                          4666 Faries Parkway
                          Decatur, IL 62526
                          Attn: General Counsel

Either Party may change the registered address to which such notice should be
sent by giving written notice to the other Party.

     11.7 INTEGRATION; ENTIRE AGREEMENT. This Agreement contains the entire
agreement of the Parties with regard to the subject matter contained herein and
supersedes all prior written and oral agreements, understandings and
negotiations, with regard to such subject matter.

     11.8 AMENDMENTS. This Agreement, including this provision, may not be
amended without a written instrument signed by duly authorized representatives
of both Parties.

     11.9 SEVERABILITY. In the event that any part of this Agreement is
adjudicated to be invalid or unenforceable because it contravenes any applicable
law or regulation, the Parties shall perform this Agreement in accordance with
their original intentions as set forth herein, corresponding as closely as
possible to the invalid or unenforceable part insofar as it is still valid under
such law or regulation and reflects the original intention of the Parties. The
validity of the remaining permissible portions of this Agreement shall remain
unaffected thereby.

     11.10 WAIVER/CUMULATIVE RIGHTS. No failure by any Party to insist upon the
strict performance of any covenant, duty, agreement or condition of this
Agreement or to exercise any right or remedy upon a breach thereof shall
constitute a waiver of any such breach or any other covenant, duty, agreement or
condition. All rights and remedies which a Party may have hereunder or by
operation of law are cumulative, and the pursuit of one right or remedy shall
not be deemed an election to waive or renounce any other right or remedy.

     11.11 NO JOINT VENTURE OR PARTNERSHIP RELATIONSHIP. Nothing contained in or
relating to this Agreement is or shall be deemed to constitute a joint venture,
partnership or agency relationship between any of the Parties hereto and no
Party shall have any authority to act for or to assume any obligation or
responsibility on behalf of the other Party.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       31

<Page>

     11.12 FURTHER ASSURANCES. Each Party shall duly execute and deliver, or
cause to be duly executed and delivered, such further instruments and do and
cause to be done such further acts and things, including without limitation the
filing of such assignments, agreements, documents and instruments, as may be
necessary or as the other Party may reasonably request in connection with this
Agreement or to carry out more effectively the provisions and purposes hereof,
or to better assure and confirm unto such other Party its rights and remedies
under thus Agreement.

     11.13 CONSTRUCTION. Except where the context otherwise requires, wherever
used the singular shall include the plural, the plural the singular, the use of
any gender shall be applicable to all genders, the word "or" is used in the
inclusive sense and the word "any" shall mean any one item, or all items, in a
referenced category. The captions of this Agreement are for convenience of
reference only and in no way define, describe, extend, or limit the scope or
intent of this Agreement or the intent of any provision contained in this
Agreement. The language of this Agreement shall be deemed to be the language
mutually chosen by the Parties and no rule of strict construction shall be
applied against either Party hereto.

     11.14 ACKNOWLEDGMENT. The Parties hereby acknowledge that all licenses
granted herein are, for the purposes of Section 365(n) of Title 11 of the U.S.
Code, licenses of rights to intellectual property as defined in said Title 11.

     11.15 COUNTERPARTS. This Agreement may he executed in any number of
counterparts, each of which shall be deemed to be an original, and all of which,
taken together, shall constitute one and the same instrument.

*    CONFIDENTIAL TREATMENT REQUESTED

                                       32

<Page>

     IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be
executed by their duly authorized representatives as of the day and year above
written.

                                        ADM POLYMER CORPORATION

                                        By: /s/ John D. Rice
                                            ------------------------------------
                                        Name: John D. Rice
                                        Title: President

                                        METABOLIX, INC.

                                        By: /s/ James J. Barber
                                            ------------------------------------
                                        Name: James J. Barber
                                        Title: President

*    CONFIDENTIAL TREATMENT REQUESTED

                                       33

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00111-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00111-of-00352.parquet"}]]